Every PubMed identifier on this site was checked against PubMed, one at a time. 21 of them were defective. Some pointed at a different paper entirely. Some pointed at a paper that had since been retracted, or at a study that administered a different drug from the one being graded. Some named a paper that, as far as EBL can establish, does not exist. All 21 are listed below, with what was cited, what that identifier actually resolves to, and what replaced it where anything did.
1858unique PubMed IDs on this site, every one checked
3.7%error rate in a corpus that had already been audited once
Every correction below is stored as a record in data.json, and this page is generated from those records at build time. It cannot show a correction that is not in the database, and it cannot hide one that is.
Read the percentage carefully, because the obvious way to compute it is wrong. The 21 corrections were all found between July 2026 and October 2026, in a re-audit of a corpus that had already been audited once. Dividing them by the 1858 identifiers the site renders TODAY would produce 1.1%, a figure that falls every time a citation is added and nothing is re-audited, which is why this page does not lead with it. The rate against the corpus actually audited is the figure on the left: 18 of the 489 identifiers this site carried in July 2026, measured by running the site's own reference counter over the archived snapshot for that date. A further 3 corrections were found after that date and are counted in the 21 above but not in that rate.
Measured, not remembered. refcount.populations()['rendered_unique'] from the current build, run over assets/data.json from the archived repository snapshot of July 2026, which already carries all 18 withdrawn_citations records including the retraction found that day. One definition of 'a PubMed identifier on this site', applied to two moments. An earlier version of this page put the figure for that date at 510; no count or combination of counts in that snapshot reproduces 510, so the measured 489 replaces it.
An earlier audit of the original citation set found a far higher error rate. That figure is not published here, because those citations no longer exist and it cannot be re-derived from this site. EBL does not publish numbers it cannot reproduce on demand, including its own.
Effect of intensity of aerobic training on VO2maxThe most oxygen the body can use during all-out exercise, a standard measure of aerobic fitness..Gormley SE · Med Sci Sports Exerc 2008
What happenedGormley et al. was named correctly in the prose. The PMIDPubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. was one digit off and landed on "Trained men display increased basal heat shock protein content of skeletal muscle", same journal, same month, adjacent identifier. Existence checks pass. Journal-and-year attribution checks pass. Only reading the title catches it.
Corrected July 2026
ProtocolAged garlic extract (480 mg/day for blood pressure; 2.4 g/day in plaque trials)
Effects of aged garlic extract on blood pressure in hypertensive patients: A systematic reviewA review that searches for every study on a question using a method set in advance, then assesses them together. and meta-analysisA study that pools the numbers from several trials into one combined estimate. of randomized controlled trialsPeople are assigned to the treatment or a comparison by chance, so the groups differ only in what they received. It is the design that can show cause and effect..Saadh MJ · Prostaglandins Other Lipid Mediat 2024
Aged garlic extract reduces blood pressure in hypertensives: a dose-response trial.Ried K · Eur J Clin Nutr 2013
What happenedSaadh et al., Prostaglandins & Other Lipid Mediators 2024: 'Effects of aged garlic extract on blood pressure in hypertensive patients: a systematic review and meta-analysis of randomized controlled trials'. PubMed now carries the publication type 'Retracted Publication'. It was one of two citations behind a Grade B and the only one supporting the blood-pressure claim. Found by a retraction sweep of every PMID on the site; it was the only one. A retracted paper passes every existence, attribution and title check, because it is still indexed and still says what it said. Replaced by Ried 2013 (PMID 23169470), a dose-response RCTRandomized controlled trial: people are assigned to the treatment or a comparison by chance, so the groups differ only in what they received. It is the design that can show cause and effect. of aged garlic extract itself, and Ried 2016 (PMID 26764326), a meta-analysis of 20 garlic trials. The grade returns to B on that evidence rather than on the retracted paper. Both replacements carry a sponsorship caveat, now flagged.
Withania somnifera (Indian ginseng) in diabetes mellitus: A systematic review and meta-analysis of scientific evidence from experimental research to clinical application.Durg S · Phytother Res 2020
Withdrawn
No replacement. The claim was corrected or the citation removed.
What happenedWrong paper. Durg et al., Phytotherapy Research 2020, is "Withania somnifera (Indian ginseng) in diabetes mellitus": Ashwagandha, for diabetes. It was the sole citation for a Bacopa cognition grade. Author, journal and year were transcribed correctly; the wrong Durg paper was pulled.
Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups.Juratli TA · J Neurooncol 2019
Effects of Blood Flow Restriction Training on Muscular Strength and Hypertrophy in Older Individuals: A Systematic Review and Meta-Analysis.Centner C · Sports Med 2019
What happenedCited as "Centner 2019 meta-analysis (Sports Med)". The PMID resolves to "Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade glioma" (J Neurooncol).
Magnitude of Muscle Strength and Mass Adaptations Between High-Load Resistance Training Versus Low-Load Resistance Training Associated with Blood-Flow Restriction: A Systematic Review and Meta-Analysis.Lixandrão ME · Sports Med 2018
What happenedCited as "Lixandrao 2018 meta-analysis (Sports Med)". The PMID resolves to Ralston, "The Effect of Weekly Set Volume on Strength Gain", correct journal, wrong paper.
Effects of low-load resistance training with blood flow restriction and swallowing training on sarcopenic dysphagia in community-dwelling older people in China: a randomised controlled trial protocol.Xing Y · BMC Geriatr 2026
Withdrawn
No replacement. The claim was corrected or the citation removed.
What happenedA randomized controlled trial PROTOCOL on sarcopenic dysphagia. A protocol has no results.
Withdrawn July 2026
Device / modalityConsumer Wearables (sleep and fitness tracking)
The Sleep of the Ring: Comparison of the ŌURA Sleep Tracker Against Polysomnography.de Zambotti M · Behav Sleep Med 2019
What happenedCited as "De Zambotti 2019, 79% epoch-by-epoch agreement vs polysomnography". The PMID resolves to "Immediate replacement of an extracted anterior tooth: a minimally invasive approach" (General Dentistry).
Corrected July 2026
Device / modalityConsumer Wearables (sleep and fitness tracking)
Assessing the Accuracy of Smartwatch-Based Estimation of Maximum Oxygen Uptake Using the Apple Watch Series 7: Validation Study.Caserman P · JMIR Biomed Eng 2024
What happenedCited for "Apple Watch VO2max validated against treadmill". The PMID resolves to "SPRED proteins and their roles in signal transduction, development, and malignancy" (Genes & Development). The claim was also false: the only validation study found POOR agreement (ICC 0.47) and used a cycle ergometer, not a treadmill.
Corrected July 2026
BiomarkerA measurable sign in the body, such as a blood test value, used to track a condition or the effect of a treatment.ESR (Sed Rate)
Erythrocyte sedimentation rate as an independent prognostic marker for mortality: a prospective population-based cohort studyAn observational study that follows a group of people over time and compares what happens to them..Fest J · J Intern Med 2019
What happenedAttributed to "Li 2015, PLoS ONE, ESR + mortality". The PMID resolves to a study of tumor-infiltrating inflammatory cells in BRAIN TUMORS. No paper matching the stated attribution was ever located; the attribution appears to have been fabricated.
The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years.Coutinho M · Diabetes Care 1999
What happenedAttributed to "DECODE 2003, Lancet, n=25,364". The PMID resolves to "Use and abuse of HOMA modeling" (Diabetes Care 2004). Not DECODE, not Lancet, not 2003, not the topic. No DECODE paper matching that attribution was located. Fabricated attribution.
Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement.Grundy SM · Circulation 2005
Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults.Ruttmann E · Circulation 2005
What happenedAttributed to "Ruttmann 2005, Circulation, n=163,944". The PMID resolves to Grundy, "Diagnosis and management of the metabolic syndrome". Ruttmann is PMID 16186419.
Corrected July 2026
BiomarkerHomocysteineAn amino acid in the blood that rises when vitamin B12, folate or B6 are low.
Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial.Schnyder G · JAMA 2002
Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis.Wald DS · BMJ 2002
What happenedAttributed to "Wald 2002, BMJ, meta-analysis". The PMID resolves to Schnyder, a folate and B12 intervention trial. Wald DS, BMJ 2002 is PMID 12446535.
Homocysteine lowering with folic acid and B vitamins in vascular disease.Lonn E · N Engl J Med 2006
What happenedAttributed to "HOPE-2 (n=5,522)". The PMID resolves to Bonaa KH, N Engl J Med 2006, "Homocysteine lowering and cardiovascular events after acute myocardial infarction", which is NORVIT: a different trial, a different population (post-MI), n=3,749. HOPE-2 is Lonn E, N Engl J Med 2006, PMID 16531613. Published the same day in the same journal with adjacent PMIDs. It survived every prior build because the PMID sat in prose rather than in pubmed_ids[], so lens 2 never checked its attribution.
Effects of heart rate variability biofeedback during exposure to fear-provoking stimuli within spider-fearful individuals: study protocol for a randomized controlled trial.Schäfer SK · Trials 2018
Withdrawn
No replacement. The claim was corrected or the citation removed.
What happenedA CLINICAL TRIAL PROTOCOL for spider-fearful individuals. A protocol has no results and cannot support a grade in either direction.
A validation study of the WHOOP strap against polysomnography to assess sleep.Miller DJ · J Sports Sci 2020
Withdrawn
No replacement. The claim was corrected or the citation removed.
What happenedMiller et al. 2020 validated a wrist strap against polysomnography for sleep measurement in 12 adults. It says nothing about biofeedback and supports no letter.
Understanding pain among older persons: Part 2-the association between pain profiles and healthcare utilisation.Kennedy N · Age Ageing 2017
Withdrawn
No replacement. The claim was corrected or the citation removed.
What happenedUnrelated paper. Kennedy et al., pain profiles and healthcare utilization. Never supported the balance-training claim it was attached to.
Withdrawn July 2026
ProtocolPsyllium husk (10 to 15 g/day) for LDL-CLow-density lipoprotein cholesterol, the cholesterol fraction most closely tied to plaque in the arteries.
Plantago consumption significantly reduces total cholesterol and low-density lipoprotein cholesterol in adults: A systematic review and meta-analysis.Zhu R · Nutr Res 2024
What happenedCited for "psyllium husk reduces LDL-C 5-10%". The PMID resolves to "The causal role of the somatosensory cortex in prosocial behavior" (eLife).
mTORA signaling pathway that controls cell growth. Turning it down is one proposed mechanism behind several longevity interventions. inhibition improves immune function in the elderly.Mannick JB · Sci Transl Med 2014
Withdrawn
No replacement. The claim was corrected or the citation removed.
What happenedAdministered RAD001 (everolimus), not rapamycin. Novartis-authored.
Effects of Magnesium Citrate, Magnesium Oxide, and Magnesium Sulfate Supplementation on Arterial Stiffness: A Randomized, Double-BlindNeither the participants nor the people assessing them know who received the real treatment until the trial ends., Placebo-Controlled Intervention Trial.Schutten JC · J Am Heart Assoc 2022
Effects of Magnesium Supplementation on Blood Pressure: A Meta-Analysis of Randomized Double-Blind Placebo-Controlled Trials.Zhang X · Hypertension 2016
What happenedAttributed to "Zhang 2016, 34-RCT meta-analysis". The PMID resolves to Schutten 2022 on magnesium salts. Zhang X, Hypertension 2016 is PMID 27402922.
Zinc for the common cold.Singh M · Cochrane Database Syst Rev 2013
Withdrawn
No replacement. The claim was corrected or the citation removed.
What happenedSingh and Das, Cochrane Database of Systematic Reviews 2013, was withdrawn by Cochrane in 2015 after errors in how its data were derived were raised (the withdrawal notice is indexed on PubMed). A withdrawn review cannot support a grade.
Withdrawn October 2026
Corrections since that audit · 211
The list above is one kind of defect: a citation taken off a record. The
corrections below are the other kind, and they are the more common one. The citation stayed and what EBL said it
showed was wrong. A paper filed as a null result that reported a significant effect. A trial and that trial's own
subgroup counted as two independent studies. A grade resting on the replicatedThe same finding reproduced by a separate research group. A result seen once can be chance or bias; a replicated one is harder to explain away. route with nothing replicating it.
None of these is visible to a check that asks whether an identifier resolves, because every one of them resolves.
They are found by reading the paper against the sentence, and they are recorded here as they are found.
CorrectionSugar-sweetened drinks added as an ungraded record: one small trial, not graded
Recordsugar-sweetened-drinks
What happenedThe nutrition page's liquid sugar entry had no citation. It now cites Maersk et al. (Am J Clin Nutr, 2012; PMID 22205311), a 6-month randomized trial in 47 overweight adults in which a liter a day of sugar-sweetened cola raised liver and visceral fat compared with milk, diet cola or water. One small trial carries no letter.
CorrectionLate dinner before sleep added as an ungraded record: one small trial, not graded
Recordlate-dinner-before-sleep
What happenedThe nutrition page's meal timing entry had no citation. It now cites Gu et al. (J Clin Endocrinol Metab, 2020; PMID 32525525), a randomized crossoverA trial design in which each participant receives both the treatment and the comparison, one after the other, and serves as their own control. trial in 20 healthy adults in which a 10 p.m. dinner raised overnight glucose compared with a 6 p.m. dinner, and sleep architecture did not differ. One small trial of one meal carries no letter.
CorrectionVitamin D3: two more large null trials added to the cardiovascular and fracture rows; both stay at D
Recordvitamin-d
What happenedA completeness check against the large vitamin D trials found two the record did not cite. ViDA (Scragg et al., JAMA Cardiol, 2017; PMID 28384800), 5,110 adults given monthly high doses, found no reduction in cardiovascular disease. DO-HEALTH (Bischoff-Ferrari et al., JAMA, 2020; PMID 33170239), 2,157 adults aged 70 and over, found no effect on nonvertebral fractures. Both agree with the existing rows, so both letters hold at D.
CorrectionGenetic testing to choose diet or supplements added: Grade D, tested and no added benefit
Recordnutrigenomic-testing
What happenedGene-test panels sold to choose diet changes and supplements now have a record. The largest randomized trial of the idea, Food4Me (Celis-Morales et al., Int J Epidemiol, 2017; PMID 27524815), gave adults in seven European countries personalized nutrition advice with and without their genotype; the genotype added nothing beyond advice based on diet alone. D on Route 2Human randomized trials have been run and did not show benefit on the stated outcome. One of the two routes to the lowest letter on EBL's scale.. Gene testing to guide medication choice is a different question and is not graded on this record.
CorrectionCaffeine timing before sleep added as an ungraded record: one small trial, not graded
Recordcaffeine-timing-and-sleep
What happenedThe nutrition page's caffeine entry had no citation. It now cites Drake et al. (J Clin Sleep Med, 2013; PMID 24235903), a randomized crossover trial in 12 healthy adults in which 400 mg of caffeine taken even 6 hours before bed shortened measured sleep by more than an hour. One small trial of one dose carries no letter.
CorrectionCocoa flavanol supplementation added as an ungraded record: primary cardiovascular endpointThe outcome a trial measures to decide whether the treatment worked, such as heart attacks, blood pressure or a symptom score. missed
Recordcocoa-flavanol-supplementation
What happenedThe nutrition page's polyphenol entry had no citation. It now cites COSMOS (Sesso et al., Am J Clin Nutr, 2022; PMID 35294962): 21,442 older adults, 500 mg of cocoa flavanols a day for a median 3.6 years, with total cardiovascular events not significantly lower and cardiovascular deaths lower as a secondary outcome. One trial that missed its primary endpointThe one outcome a trial names in advance as its main test. Results on other outcomes carry less weight. carries no letter.
CorrectionCold-water immersion: soreness and short-term recovery after strenuous exercise graded B, heart rate variability after immersion graded C, on their own rows; two 2026 reviews added
Recordcold-water-immersion
What happenedThe record had set aside post-exercise recovery trials as a use it did not grade, while the page itself described them. Recovery now has its own row. Bleakley et al. (Cochrane, 2012; PMID 22336838), Moore et al. (Sports Med, 2022; PMID 35157264), Moore et al. (Sports Med, 2023; PMID 36527593) and Machado et al. (Sports Med, 2016; PMID 26581833) pool randomized trials from independent groups showing less soreness after strenuous exercise; self-reported soreness caps the letter at B under the written definition. Berjisian et al. (Sports Med Open, 2026; PMID 42816732) confirms both the recovery benefit and the harm to strength gains and joins both rows. Ngandeu Schepanski et al. (Front Physiol, 2026; PMID 42819812) joins the Mood row: benefit not established. Heart rate variability after immersion has its own row at C: the pooled acute rise replicates (Jdidi et al., J Therm Biol, 2024; PMID 38663342; Galvez-Rodriguez et al., Physiother Res Int, 2025; PMID 39918163; Almeida et al., J Sci Med Sport, 2016; PMID 26614422; Al Haddad et al., Int J Sports Physiol Perform, 2012; PMID 21941017), but heart rate variability is not an established stand-in for a clinical outcome, which caps it at C. Headline letter unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
Correction2-HOBA added: Grade D, tested and harm found on atrial fibrillation
Record2-hoba
What happened2-HOBA is sold for inflammation and healthy aging and was offered at a longevity conference by a sponsor, so it now has a record. Its only randomized trial on a clinical outcome, Yoneda et al. (Circ Arrhythm Electrophysiol, 2025; PMID 40709466), found atrial fibrillation came back more often on 2-HOBA than on placeboAn inactive substitute made to look like the real treatment, so participants cannot tell which one they received. after ablation (60.5 against 35.9 percent). The healthy-volunteer studies (Pitchford et al., BMC Pharmacol Toxicol, 2020; PMID 31907026; Rathmacher et al., Inflammation, 2023; PMID 36935449) measured safety and blood markers only. Grade D on Route 2 with the harm badge, under the written definition.
CorrectionBeetroot and glutathione: product forms that are not the graded form are named and kept out of the letter
Recordbeetroot
What happenedTwo products sold at a longevity conference sit near graded records without being the graded form. Lozenges combining nitrite with plant nitrate now appear on the beetroot record as a separate form, with their three trials (Zand et al., Nutr Res, 2011; PMID 21530799; Houston et al., J Clin Hypertens, 2014; PMID 24962851; Bryan et al., Am J Med, 2023; PMID 37356641), not counted in the beetroot letter; the only trial on a clinical outcome was null. Glutathione now states that its grade is for the oral form: a transdermal form did not raise plasma reduced glutathione in the one trial comparing routes (Kern et al., Med Sci Monit, 2011; PMID 22129897). Letters unchanged.
CorrectionExogenous ketones added: Grade C for blood glucose after meals and heart failure hemodynamics; performance, migraine and blood pressure tested without benefit
Recordexogenous-ketones
What happenedKetone drinks were sold at a longevity conference by a sponsor, so they now have a record. Falkenhain et al. (Adv Nutr, 2022; PMID 35380602) found single doses lower blood glucose across 43 trials, and Berg-Hansen et al. (Circulation, 2024; PMID 38533643) found higher cardiac output in heart failure over two weeks: C, measured markers. Brooks et al. (Int J Sport Nutr Exerc Metab, 2022; PMID 35042186), Putananickal et al. (Cephalalgia, 2022; PMID 34541914) and Marcotte-Chenard et al. (J Diet Suppl, 2024; PMID 38145410) found no benefit on endurance, migraine or blood pressure: D on Route 2.
CorrectionCarotid ultrasound added as an ungraded measurement: small added value for predicting heart attack and stroke; repeat scans not supported
Recordcarotid-imt-ultrasound
What happenedCarotid scans were sold direct to consumers at a longevity conference, so they now have a record. Like DEXA, the scan is a measurement and carries no letter. Den Ruijter et al. (JAMA, 2012; PMID 22910757) found intima-media thickness added little to standard risk factors across 45,828 people, and Lorenz et al. (Lancet, 2012; PMID 22541275) found change between two scans did not predict events.
CorrectionREMS ultrasound bone densitometry added as an ungraded measurement: agrees with DXA on a single scan, driven largely by typed-in age and weight
Recordrems-bone-densitometry
What happenedREMS bone scans were sold direct to consumers at a longevity conference, so they now have a record. Like DEXA, the scan is a measurement and carries no letter. Cortet et al. (Bone, 2021; PMID 33278653) found it classified osteoporosis close to DXA, and Chan et al. (Osteoporos Int, 2026; PMID 41872364) found the typed-in age and weight explained most of its result.
CorrectionCreatine, strength in older adults: holds at A; two newer pooled analyses added to the record
Recordcreatine
What happenedAn outside audit of October 2026 read the 2025 pooled analysis of 69 trials (Kazeminasab et al.; PMID 40944139) as removing the A, because its older-adult subgroup was not significant. That subgroup sits inside an all-ages pooling and is not a failed replication; a pooled analysis confined to older adults and adults with chronic disease (Davies et al., 2024; PMID 38417175; 33 trials) found upper-body and handgrip strength higher on creatine, and the independent trials behind the A are unchanged. The letter holds at A, and the subgroup is now stated on the record beside the two null long trials already there.
CorrectionVitamin D3, falls: holds at C; the 2026 BMJ pooled analysis added to the record
Recordvitamin-d
What happenedAn outside audit of October 2026 read Massé et al. (BMJ, 2026; PMID 42161415), 69 trials, no effect of vitamin D alone on falls with high certainty, as moving this use to D. Wei et al. (Front Endocrinol, 2022; PMID 36034418), 38 trials, found fewer falls at 700 IU a day or more. Pooled analyses that disagree are C under the written definition, so the letter holds and both are now on the record.
CorrectionSermorelin: growth hormone and cognition rows flagged for review; a placebo-controlled trial was missed
Recordsermorelin
What happenedAn outside audit of October 2026 identified Vitiello et al. (Neurobiol Aging, 2006; PMID 16399214), a six-month placebo-controlled trial of growth hormone-releasing hormone (GHRH 1-29) in 89 healthy older adults with cognitive outcomes. The record said no placebo-controlled trial of sermorelin exists; that sentence is withdrawn. The absence search used the drug's names and missed a trial indexed under the hormone's name. Both rows carry a review flag and stay D until the paper is read in full.
CorrectionALCAR, EGCG and colostrum: papers on other uses moved out of the grade evidence
Recordalcar
What happenedAn outside audit of October 2026 found papers on other uses among the citations behind three single letters: neuropathy papers under ALCAR's cognition letter (PMIDs 23733756, 25751285, 29361042, 31201734; the Sima trial stays, because the record's dosing-time line rests on it), glucose, blood-pressure and safety papers under EGCG's LDL letter (PMIDs 23426037, 25176280, 26051348), and immune and respiratory-symptom analyses under colostrum's permeability letter (PMIDs 27462401, 32276466). They stay on each page, described in the record's text, and no longer count as evidence for the letter.
Corrected October 2026
CorrectionMelatonin, delayed sleep phase: why the letter moved B to A and back to B in October
Recordmelatonin
What happenedTwo entries in this log record the delayed sleep phase use rising from B to A and returning to B soon after. Nothing in the evidence changed between them. The upgrade counted Kayumov et al. (Psychosom Med, 2001; PMID 11211063) as the independent replication of Sletten et al. (PLoS Med, 2018; PMID 29912983). The Kayumov trial enrolled 22 people, and the rule this log publishes requires more than 30 participants before a trial can move a grade, so it could not serve as that replication. The A was an error in applying EBL's own rule, and the same rule reversed it. The use is B, as it was before the upgrade, and both entries stay published so the reversal can be checked. Noted by the editor (Arnold Sandlow, D.C.).
CorrectionThree medication depletionA fall in a nutrient's level caused by a medication, for example through reduced absorption or increased loss. rows lowered from critical to moderate: a severity label may not rest on mechanistic evidence alone
Recordsite-wide
What happenedThree depletion rows carried the label critical over evidence with no human trial behind it: statins and geranylgeraniol (Osaki et al., 2026; PMID 42323079, a mouse knockout), corticosteroids and magnesium (Rude, Magnes Res, 1999; PMID 10612083, a rat study), and insulin and magnesium (Paolisso et al., Am J Clin Nutr, 1992; PMID 1595589, a supplementation trial, not a depletion finding). The strongest warning on a page may not rest on its weakest evidence, so each now reads moderate, with its evidence label unchanged. A build check now stops any future row that pairs critical with mechanistic evidence.
CorrectionStatins: vitamin D removed from the depletion list, because the randomized trials found the opposite
Recordsite-wide
What happenedThe statin record listed vitamin D3 as a mild depletion while its own evidence said the opposite: across three randomized trials, statins raised serum vitamin D by 2.71 ng/mL (Mazidi et al., Eur J Clin Invest, 2017; PMID 27859044), and only observationalResearch that watches what people already do rather than assigning a treatment. It can show that two things travel together, not that one causes the other. designs showed a fall. The check report therefore told statin users their vitamin D could fall, which the trials do not support. The row is removed and the statin record now states why vitamin D is not listed, with the same citation.
CorrectionInositol: the second meta-analysis described correctly; it compared inositol with active treatments, not placebo. B unchanged
Recordinositol
What happenedThe record said both cited meta-analyses found myo-inositol improved insulin resistance in PCOS. Greff et al. (Reproductive Biology and Endocrinology, 2023; PMID 36703143) did, against placebo, across 26 trials. Jethaliya et al. (Reprod Sci, 2022; PMID 35477841) found no significant difference in fasting insulin, fasting glucose or HOMA, but its comparators were folic acid, metformin and oral contraceptives, not placebo. The record now says so. The B rests on the placebo-controlled pooled evidence and is unchanged.
CorrectionFenugreek: the cited pooled analysis described correctly and three independent pooled analyses added; B unchanged
Recordfenugreek
What happenedThe record rested on one pooled analysis and said fenugreek lowered fasting glucose and HbA1cA blood test that reflects average blood sugar over the previous two to three months.. That analysis, Shabil et al. (Medicina (Kaunas), 2023; PMID 36837450), found HbA1c lower but no change in fasting glucose. A PubMed search for every pooled analysis of fenugreek on blood glucose found three more that agree on both markers: Kim et al. (Int J Mol Sci, 2023; PMID 37762302), 10 randomized trials in type 2 diabetes or prediabetes; Fakhr et al. (Pharmacol Res, 2023; PMID 36470549), 29 randomized trials; and Neelakantan et al. (Nutr J, 2014; PMID 24438170), which also found the effect confined to medium or high doses in people with diabetes and most trials of low quality. Replicated pooled evidence on glycemic surrogates is the written B definition, so the letter is unchanged; the record now states what each analysis found and the search that found them.
CorrectionZinc: the withdrawn Cochrane review replaced; B narrowed to adults taking high-dose lozenges
Recordzinc
What happenedThe zinc record rested on one citation, Singh and Das (Cochrane Database of Systematic Reviews, 2013; PMID 23775705), which Cochrane withdrew in 2015. It is replaced by Science et al. (CMAJ, 2012; PMID 22566526), Hemilä et al. (Br J Clin Pharmacol, 2016; PMID 27378206), Hemilä and Chalker (BMC Fam Pract, 2015; PMID 25888289) and Hemilä et al. (BMJ Open, 2020; PMID 31980506). They agree that lozenges supplying about 75 to 92 mg of zinc a day, started early, shorten colds in adults by roughly two and a half days, that a 13 mg lozenge did not, and that children showed no significant effect. The B now names that use, form and dose; children are graded C; deficiency correction is no longer part of the graded use.
CorrectionChondroitin: what the cited papers found, corrected; the B scoped to the pharmaceutical-grade preparation
Recordchondroitin
What happenedThe record said Rabade et al. (Inflammopharmacology, 2024; PMID 38581640) and Gregori et al. (JAMA, 2018; PMID 30575881) found small benefits from chondroitin, often with glucosamine. Gregori found no long-term pain benefit for chondroitin, and Rabade found the combination with glucosamine improved neither pain nor function. A PubMed search for every randomized trial and pooled analysis found the B rests on one preparation: pharmaceutical-grade chondroitin sulfate at 800 mg a day (Reginster et al., Ann Rheum Dis, 2017; PMID 28533290; Honvo et al., Adv Ther, 2019; PMID 30879253). Chondroitin as generally sold, and the combination with glucosamine, are graded C.
CorrectionAstaxanthin: the B narrowed to skin moisture and elasticity; five other uses graded C
Recordastaxanthin
What happenedThe record listed antioxidant activity, eye health, skin photoprotection, cardiovascular support and exercise recovery under one B. A PubMed search and a reading of every cited paper found the B holds only for skin moisture and elasticity (Zhou et al., Nutrients, 2021; PMID 34578794). Each other use is now graded on its own evidence and is C. The descriptions of Tominaga et al. (PMID 22428137) and Park et al. (PMID 20205737) were also corrected: Tominaga's moisture result was a trend, and Park found some inflammatory markers rose at 8 mg.
CorrectionGinkgo: the B scoped to dementia at 240 mg a day; mild cognitive impairment graded C
Recordginkgo-biloba
What happenedThe record called both of its citations meta-analyses of EGb 761 covering dementia and mild cognitive impairment. Liao et al. (PMID 32658034) did not name EGb 761, and Riepe et al. (PMID 39895346) covered mild dementia only. A PubMed search added Tan et al. (J Alzheimers Dis, 2015; PMID 25114079) and Gauthier and Schlaefke (Clin Interv Aging, 2014; PMID 25506211) for dementia, the dissenting Birks and Grimley Evans (Cochrane, 2009; PMID 19160216) and Thancharoen et al. (Drugs Aging, 2019; PMID 30937879), and the one blinded trial in mild cognitive impairment, Gavrilova et al. (Int J Geriatr Psychiatry, 2014; PMID 24633934), which is graded C on its own.
CorrectionPhotobiomodulation: the B scoped to neck and tendinopathy pain; low back pain graded C
Recordphotobiomodulation-skin-msk
What happenedThe B rested on one meta-analysis of neck pain and a review described as covering skin, which it does not. A PubMed search added Yap and Lim (J Back Musculoskelet Rehabil, 2025; PMID 40437920), tendinopathy, positive; Tomazoni et al. (J Physiother, 2020; PMID 32680739), low back pain, no worthwhile effect against shamA fake version of a procedure or device used as the comparison, so participants cannot tell which one they received.; and Glazov et al. (Acupunct Med, 2016; PMID 27207675), low back pain, subgroups only. Neck and tendinopathy pain hold B; low back pain is C.
CorrectionHRV biofeedback: the B rests on randomized evidence for anxiety; stress graded C
Recordhrv-biofeedback
What happenedThe B rested on Goessl et al. (Psychol Med, 2017; PMID 28478782), described as consistent randomized evidence; its abstract does not say the studies were randomized. A PubMed search found Lehrer et al. (Appl Psychophysiol Biofeedback, 2020; PMID 32385728), restricted to randomized controlled studies, and a sham-controlled trial, Minjoz et al. (Biol Psychol, 2026; PMID 41905438). Anxiety holds B on those. Stress is graded C because Vann-Adibe et al. (2026; PMID 41310318) found no pooled effect. A sleep-tracker validation study was removed; it never concerned biofeedback.
CorrectionNattokinase: trial descriptions corrected; B for blood pressure unchanged
Recordnattokinase
What happenedJensen et al. (PMID 27785095) reported a significant between-group difference for diastolic pressure only; the record said both. Hodis et al. (PMID 33843667) enrolled healthy people not selected for raised pressure, which the record now says. Li et al. (PMID 39076715) also found lipids moved in the unfavorable direction, now stated. A duplicated description of Yang et al. (PMID 19786378) was removed, along with a sentence about red yeast rice that no cited paper supported. A PubMed search found no new trial; the letter is unchanged.
What happenedThree trial results were written as differences against a control when the papers report changes within the training group: Ferreira et al. (PMID 21985749), Ramos-Barrera et al. (PMID 32730174) and Ublosakka-Jones et al. (PMID 29604403), whose difference against its control was about 15 mmHg, not 20. The record also counted sleep apnea severity under its B; three pooled analyses found no improvement (Zuo et al., 2026; PMID 41721779; Chen et al., 2023; PMID 36576599; Silva de Sousa et al., 2024; PMID 37258418), so that use is graded D. Blood pressure holds B on a sham-controlled trial and two further pooled analyses (Li et al., 2023; PMID 37803506; Craighead et al., 2022; PMID 36107991).
CorrectionREHIT: the B now rests on trials of REHIT itself; glucose and blood pressure graded C
Recordrehit
What happenedThe B rested on two meta-analyses of sprint and interval training in general (Sloth et al., PMID 23889316; Milanović et al., PMID 26243014), which the record itself said did not test REHIT. A PubMed search found randomized trials of the REHIT protocol from three independent groups, all finding VO2max rose: Metcalfe et al. (Eur J Appl Physiol, 2012; PMID 22124524), Cuddy et al. (Int J Environ Res Public Health, 2019; PMID 30736402) and Hu et al. (J Exerc Sci Fit, 2025; PMID 40689309). The letter is unchanged and now rests on them. Insulin sensitivity and blood pressure are graded C.
CorrectionPlant sterols: "with largest meal" removed from the protocol name; B unchanged
Recordplant-sterols-1-6-2-g-day-with-largest-meal
What happenedThe protocol was named for taking plant sterols with the largest meal. The cited meta-analysis, Ras et al. (Br J Nutr, 2014; PMID 24780090), pooled plant sterols and stanols and did not test meal timing; its post hoc comparison found solid foods worked better than drinks. The name now states only the dose, and the description states what the analysis found. The letter is unchanged.
CorrectionStructured exercise after cancer treatment: "early-stage" corrected to "non-metastatic"; B unchanged
Recordstructured-exercise-after-cancer-treatment
What happenedThe protocol said it covered early-stage cancer. Its deciding trial, CHALLENGE (Courneya et al., N Engl J Med, 2025; PMID 40450658), enrolled people with resected high-risk stage II or stage III colon cancer, which readers would not call early-stage. The scope now reads non-metastatic cancer, which is what the trials and the pooled analysis covered. The letter is unchanged.
CorrectionTrehalose: Route 2 re-based on the oral trial in healthy older adults, the 2 g dose removed, the ALS safety signal recorded, endpoint type corrected
Recordtrehalose
What happenedRoute 2 rested on Jamialahmadi et al. (Biomed Pharmacother, 2022; PMID 35045351), 15 heart attack survivors given intravenous trehalose, and grade_basis never discussed Kaplon et al. (Aging, 2016; PMID 27208415), the only oral trial in healthy middle-aged and older adults, whose full-sample primary analysis was not significant. Kaplon is now the basis and Jamialahmadi supporting context, with its population corrected. The dose field's 2 g figure matched no trial and is replaced by the doses studied. The ALS platform trial (HEALEY, Lancet Neurol, 2025; PMID 40409314) now records serious adverse events in 16 against 7 percent. Added: Yap et al. (Parkinsonism Relat Disord, 2024; PMID 38843619), oral trehalose in spinocerebellar ataxia, null at interim; Yoshizane et al. (Nutr J, 2020; PMID 32646428), run by a trehalose manufacturer. endpoint_type corrected from hard to surrogate. D Route 2 unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionTurkey tail: the graded endpoint moved from immune measures to survival after cancer surgery, the positive meta-analyses and the three recent null trials added, form and dose stated
Recordturkey-tail
What happenedThe record graded immune measures, but its only citation, the Cochrane review (Pilkington et al., 2022; PMID 36445793), studied survival and adverse effects in colorectal cancer, not immune markers, and the ref did not say what it found. The endpoint is now overall survival after curative resection with PSK added to chemotherapy. Added: Sakamoto et al. (Cancer Immunol Immunother, 2006; PMID 16133112) and Oba et al. (Cancer Immunol Immunother, 2007; PMID 17106715), positive pooled survival; Miyake et al. (Surg Today, 2018; PMID 28634730), Okuno et al. (Cancer Chemother Pharmacol, 2018; PMID 29094178) and Ogawa et al. (Anticancer Res, 2024; PMID 38307591), null; Zhong et al. (Front Pharmacol, 2019; PMID 31333449), immune markers pooled with Ganoderma products. The dose field now states PSK at about 3 g/day and that retail products are not shown equivalent. C unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionUrolithin A: best use restated around the muscle endpoints that failed, the 2026 meta-analysis and the two null trials added, the phase 1 trial relabeled, the safety claim narrowed
Recordurolithin-a
What happenedbest_use led with mitophagy and mitochondrial health, which are markers, and said safety is well established on 4 weeks to 4 months of exposure in a few hundred people. It now names muscle function, where both larger trials missed their pre-registered primary endpoints, and states the exposure. Added: Dao et al. (Front Nutr, 2026; PMID 42559151), meta-analysis with the 6-minute walk inconclusive at low certainty; Jamialahmadi et al. (Rev Recent Clin Trials, 2024; PMID 38415449), null in heart failure; Monsalve Acevedo et al. (Front Nutr, 2025; PMID 41245402), a small positive pilot in young soccer players. Andreux et al. (Nat Metab, 2019; PMID 32694802) is relabeled as a phase 1 trial with safety as its primary outcome. The maker's funding of five trials was already stated trial by trial. C unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionVascanox HP: the open-labelEveryone in the trial knows which treatment they are receiving, so expectations can shape the results, especially for symptoms people report themselves. study no longer typed as a randomized trial, its population and diastolic result corrected, the absence check re-run
Recordvascanox
What happenedevidence_type read rct on a record whose only study is open-label and uncontrolled and whose best use says no randomized trial has been run; it now reads as a single uncontrolled study. The ref described 12 hypertensive adults; Houston et al. (Cureus, 2023; PMID 37849591) enrolled adults with elevated pressure or mild hypertension, and the diastolic fall was confined to those with raised diastolic pressure. The ref now also says the paper's efficacy conclusion is beyond what the design can show. The absence check was re-run with the same result. D Route 1No human randomized trial has been run, so the record rests on animal or mechanistic evidence only. One of the two routes to the lowest letter on EBL's scale. unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionVitamin D3: the dose line tied to each row's trials, the replete-adult rows corrected and relabeled as not selected for vitamin D status, D-Health cardiovascular and the cancer-mortality subgroup added, grade_basis brought in line with the B headline
Recordvitamin-d
What happenedThe dose field said the graded trials used 2,000 to 5,000 IU/day; the positive fracture trial used 800 IU/day with calcium, VITAL 2,000 IU/day, D-Health 60,000 IU monthly and FIND 1,600 or 3,200 IU/day, now stated. grade_basis and ref still read Headline Grade C after the October calcium row set the headline at B; both now say B and why. The replete-adult fracture row said it did not contradict a Grade B for deficiency, which moved to D in October; corrected, with D-Health (Waterhouse et al., 2023; PMID 37011645) and FIND (Rikkonen et al., Bone, 2026; PMID 42704968) added, including FIND's higher fracture count at 1,600 IU/day. The cardiovascular row adds D-Health (Thompson et al., BMJ, 2023; PMID 37380191), borderline and consistent with no effect; the cancer row adds Keum et al. (Br J Cancer, 2022; PMID 35676320), null on incidence with a daily-dosing subgroup signal on cancer mortality. The trial populations now read not selected for vitamin D status rather than replete. All letters unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionVitamin E: the letter re-based on replicated no-benefit with the SELECT harm stated in context, PHS II and the other large trials added, ATBC relabeled
Recordvitamin-e-supplemental
What happenedgrade_basis said the prostate finding carries the letter and set ATBC against SELECT as two trials of the same question. ATBC (N Engl J Med, 1994; PMID 8127329) tested 50 mg/day in smokers; it is now labeled a different dose and population. The D now rests on replicated no-benefit: SELECT's primary report (Lippman et al., JAMA, 2009; PMID 19066370), the Physicians' Health Study II (Gaziano et al., JAMA, 2009; PMID 19066368), the Women's Health Study (Lee et al., JAMA, 2005; PMID 15998891), HOPE-TOO (Lonn et al., JAMA, 2005; PMID 15769967) and the USPSTF review (O'Connor et al., JAMA, 2022; PMID 35727272), all added. The SELECT harm stays as the badge, now with its context: nonsignificant at the primary report, significant on follow-up that ran past the end of supplementation, not reproduced by PHS II. HOPE-TOO's heart failure finding and the hemorrhagic stroke signal (Loh et al., Stroke Vasc Neurol, 2021; PMID 33109618) added. D Route 2, harm found, unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionWeekend-warrior protocol: the 'no prior randomized trial' claim narrowed to a single weekly session, fat mass named as the primary outcome, the two-session trials added
What happenedgrade_basis said no prior randomized trial had tested this scheduling question; Meyer et al. (Eur J Cardiovasc Prev Rehabil, 2006; PMID 16874148) randomized adults to two consecutive weekend sessions and Tripp et al. (Scand J Med Sci Sports, 2025; PMID 39921357) to two against four sessions at matched volume. Neither tested one session, so the claim now reads that no other randomized trial has tested a single weekly session in adults, with both trials described. The endpoint now names fat mass as the primary outcome and VO2max as secondary, and endpoint_type reads surrogate. C unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionWhole-body MRI screening: the 2020 paper relabeled as a review, the per-subject cancer figures and three newer pooled analyses added, Route 1 named in words
Recordwhole-body-mri-screening
What happenedThe ref called Zugni et al. (Cancer Imaging, 2020; PMID 32393345) a systematic review; it is a review and recommendations without formal risk-of-bias appraisal, now labeled so, with its per-subject figures added (cancer suspected in 1.8 percent, confirmed in 1.1 percent). Added: Kwee et al. (J Magn Reson Imaging, 2019; PMID 30932247), Martins da Fonseca et al. (Eur Radiol, 2026; PMID 40884613) and Ahsan et al. (J Gen Intern Med, 2026; PMID 42823587), all pooling yield studies with no outcome data, and the 2026 Cochrane protocol (Chen et al., Cochrane Database Syst Rev, 2026; PMID 42639816). grade_basis now names Route 1 in words. The absence check was re-run with the same result. D Route 1 unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionAlcohol reduction: the Malmo randomized trial found on re-running the absence check; mortality graded C on its own row
Recordalcohol-reduction
What happenedThe record said no randomized trial had assigned people to drink less and measured mortality. Re-running its stored search found Kristenson et al. (Alcohol Clin Exp Res, 1983; PMID 6135365): 585 middle-aged Malmo men with heavy drinking randomized to counseling to cut down or a letter, with mortality about half as high over 6 years in the intervention group (60-month report, Kristenson et al., Alcohol, 1985; PMID 2862882). A single unreplicated trial on a hard endpointAn outcome that matters directly to a person and is counted without judgment, such as death, heart attack, stroke or fracture. is C, now its own row. The headline stays B on blood pressure, and the record's endpoint field, which still named mortality, now names blood pressure. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionHMB: the sarcopeniaAge-related loss of muscle mass and strength. trials read individually; B confirmed under EBL's written grade rules, with the reason now resting on the trials
Recordhmb
What happenedThe sarcopenia use rested on a pooled analysis (Gu et al., Maturitas, 2025; PMID 39999663) and was held below A by judgment. The placebo-controlled trials were read individually: Yang et al. (J Nutr Health Aging, 2023; PMID 37248756) found handgrip 4.6 kg higher across the whole sample; Meza-Valderrama et al. (Arch Gerontol Geriatr, 2024; PMID 38171034) found it higher in women only. Handgrip qualifies for A, but a benefit not replicated across independent groups is B under the written definition, so B stands, now for that stated reason. Nasimi et al. (J Am Med Dir Assoc, 2021; PMID 33067129) tested a fortified food, and Wu et al. (Crit Care, 2023; PMID 38102705) found no effect of HMB alone in intensive care. Applied the written grade definition at the editor's request of October 2026 (Arnold Sandlow, D.C.).
CorrectionNAC: COPD exacerbations re-adjudicated by the editor and kept at C
Recordnac
What happenedZheng et al. (Lancet Respir Med, 2014; PMID 24621680), PANTHEON, reduced exacerbations at 600 mg twice daily in moderate to severe COPD. Tse et al. (Chest, 2013; PMID 23348146), HIACE, found the same as a secondary endpointAn outcome a trial also measures but did not choose as its main test. in 120 patients, with a manufacturer's employee among the authors. Zhou et al. (Nat Commun, 2024; PMID 39349461), from the PANTHEON group and without commercial funding, found no reduction at the same dose in mild to moderate disease, a population that overlaps the moderate band. The editor kept the use at C in October 2026: the replication is not strong enough to carry the letter higher. No letter changed (Arnold Sandlow, D.C.).
CorrectionVitamin D3 with calcium for fractures: the B is now scoped to older adults living in institutions
Recordvitamin-d
What happenedThe B row was labeled for institutionalized or deficient older adults. The positive trial (Chapuy et al., N Engl J Med, 1992; PMID 1331788) and the institutional benefit in the Cochrane review (Avenell et al., 2014; PMID 24729336) are in people living in institutions, while the two largest community trials were null (Jackson et al., N Engl J Med, 2006; PMID 16481635; Grant et al., Lancet, 2005; PMID 15885294), and vitamin D3 alone in deficient or older adults is graded D on its own row. The label now names the population the trials support. The letter is unchanged.
CorrectionTamoxifen now has its own medication record, separate from the aromatase inhibitors
Recordsite-wide
What happenedTamoxifen was listed under the aromatase inhibitor record, so a reader who entered it was shown that record's bone-loss row. The trial the row cites (Eastell et al., J Clin Oncol, 2008; PMID 18309940, the ATAC bone substudy) found continued bone loss on anastrozole and not on tamoxifen. Tamoxifen is now its own record with no depletion recorded, and the DIM interaction on record for women taking tamoxifen still appears when both are entered in the check.
CorrectionPterostilbene: lipids and blood pressure graded as separate uses
Recordpterostilbene
What happenedThe review asked whether the D Route 2 should stand on the LDL rise or blood pressure should be graded as its own use. Under the written definitions both hold, so both are now on the record: LDL cholesterol in adults with raised cholesterol, D Route 2, tested and harm found; blood pressure, C, one positive trial (Riche et al., Evid Based Complement Alternat Med, 2014; PMID 25057276). Headline letter unchanged at D. Closes the review opened October. Applied by the written grade definitions, October 2026.
CorrectionCoQ10, heart failure: B holds under the written rule; not-replicated flag removed; use scoped to heart-failure events including hospitalization
Recordcoq10
What happenedThe replication search of October found what the record already cited: Morisco et al. (Clin Investig, 1993; PMID 8241697), an independent Naples multicenter trial of 641 NYHA class III to IV patients, in which hospitalization for worsening heart failure fell from 118 to 73 over one year, with the Cochrane review (Al Saadi et al., 2021; PMID 35608922) pooling it with Q-SYMBIO (Mortensen et al., 2014; PMID 25282031) for that outcome. The written B requires a trial supported by further trials rather than standing alone, which this meets; it does not require independent replication of the pivotal endpoint, which is the A requirement. The flag said the finding was never repeated, which is false for hospitalization and true for mortality, so the flag comes off and the use is named for the events the two trials share, with the mortality result stated as single-trial in the reading. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionInspiratory muscle training: B holds under the written rule; not-replicated flag removed; blood-pressure populations stated
Recordinspiratory-muscle-training
What happenedThe replication search of October found four further randomized trials in which inspiratory muscle training lowered blood pressure against sham or control: Vranish et al. (Sleep, 2016; PMID 27091540) and Ramos-Barrera et al. (J Appl Physiol, 2020; PMID 32730174) in adults with sleep apnea, Ferreira et al. (Int J Cardiol, 2013; PMID 21985749) in hypertensive patients, and Ublosakka-Jones et al. (Exp Gerontol, 2018; PMID 29604403) in older adults with treated systolic hypertension. They repeat the direction and size of Craighead et al. (J Am Heart Assoc, 2021; PMID 34184544) in different populations. The written B asks for a trial supported by further trials, which this is; independence of groups is the A requirement, and blood pressure is a surrogate that caps the letter at B regardless. The flag comes off, and the record names the populations in which the finding has been repeated and the one in which it has not. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionNot-replicated flag removed: the letter rests on pooled randomized evidence
Recordplant-sterols-1-6-2-g-day-with-largest-meal
What happenedThe record carried a not-replicated flag while its B rested on a 124-study meta-analysis of LDL lowering (Ras et al., Br J Nutr, 2014; PMID 24780090). The flag describes a single trial nobody has repeated; a meta-analysis of independent randomized trials is replication by definition, and what caps this letter at B is the endpoint, not the absence of a second trial. Flag removed, letter unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionNot-replicated flag removed: the letter rests on pooled randomized evidence
Recordsleep-restriction-treatment-cbt-i
What happenedThe record carried a not-replicated flag while its B rested on a 20-trial meta-analysis (Trauer et al., Ann Intern Med, 2015; PMID 26054060). The flag describes a single trial nobody has repeated; a meta-analysis of independent randomized trials is replication by definition, and what caps this letter at B is the endpoint, not the absence of a second trial. Flag removed, letter unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
What happenedThe record carried a not-replicated flag while its B rested on a pooled analysis of randomized trials (Goyal et al., JAMA Intern Med, 2014; PMID 24395196). The flag describes a single trial nobody has repeated; a meta-analysis of independent randomized trials is replication by definition, and what caps this letter at B is the endpoint, not the absence of a second trial. Flag removed, letter unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
What happenedThe record carried a not-replicated flag while its B rested on the Goyal 2014 pooled analysis (JAMA Intern Med; PMID 24395196). The flag describes a single trial nobody has repeated; a meta-analysis of independent randomized trials is replication by definition, and what caps this letter at B is the endpoint, not the absence of a second trial. Flag removed, letter unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionNot-replicated flag removed: the letter rests on pooled randomized evidence
Recordphotobiomodulation-skin-msk
What happenedThe record carried a not-replicated flag while its B rested on a meta-analysis of randomized trials in neck pain (Chow et al., Lancet, 2009; PMID 19913903). The flag describes a single trial nobody has repeated; a meta-analysis of independent randomized trials is replication by definition, and what caps this letter at B is the endpoint, not the absence of a second trial. Flag removed, letter unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionNot-replicated flag removed: the letter rests on pooled randomized evidence
Recordwhole-body-vibration
What happenedThe record carried a not-replicated flag while its B rested on a 2026 meta-analysis of randomized trials on bone mineral density (Chen et al., BMC Musculoskelet Disord, 2026; PMID 41559705). The flag describes a single trial nobody has repeated; a meta-analysis of independent randomized trials is replication by definition, and what caps this letter at B is the endpoint, not the absence of a second trial. Flag removed, letter unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionNot-replicated flag removed: the letter rests on pooled randomized evidence
Recordhrv-biofeedback
What happenedThe record carried a not-replicated flag while its B rested on a pooled analysis of randomized trials (Goessl et al., Psychol Med, 2017; PMID 28478782). The flag describes a single trial nobody has repeated; a meta-analysis of independent randomized trials is replication by definition, and what caps this letter at B is the endpoint, not the absence of a second trial. Flag removed, letter unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionBerberine protocol: not-replicated flag removed; name follows the placebo-controlled dose
Recordberberine-500-mg-3-day-with-meals
What happenedPlacebo-controlled replication is on the record: Zhang et al. (J Clin Endocrinol Metab, 2008; PMID 18397984), PREMOTE (PMID 33024120), Ming 2021 (PMID 34365978) and Zhao 2023 (PMID 37598753), so the flag applied only to the metformin comparison, which the reading already confines to the 36-person pilot (Yin et al., Metabolism, 2008; PMID 18442638). Flag removed. The written B attaches to the dose the trials used, and those trials gave 1.0 to 1.2 g/day where the name said 1.5 g/day, so the name now reads Berberine 1.0 to 1.2 g/day (with meals). Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionAshwagandha protocol: not-replicated flag removed
Recordashwagandha-ksm-66-300-mg-at-bedtime
What happenedThe B rests on Langade et al. (Cureus, 2019; PMID 31728244) and a five-trial meta-analysis of randomized sleep trials (Cheah et al., PLoS One, 2021; PMID 34559859). Pooled randomized evidence is replication under the written rule; what the pooling does not show is a second trial of the same extract at the same dose, which the record states and which is not what the flag means. Flag removed, letter unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
What happenedThe description claimed improved sleep quality and sleep onset in multiple randomized trials and named delivery apps; the only citation, Goyal et al. (JAMA Intern Med, 2014; PMID 24395196), pooled anxiety, depression and pain. A claim with no trial behind it does not stay on a graded record, so the description now states what the pooled analysis found and says sleep is not graded. The not-replicated flag contradicted the pooled evidence and is removed. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionPterostilbene: blood pressure graded as its own use at C; headline stays D Route 2 on the LDL harm
Recordpterostilbene
What happenedThe one randomized trial (Riche et al., Evid Based Complement Alternat Med, 2014; PMID 25057276) raised LDL 17.1 mg/dL and lowered blood pressure 7.8/7.3 mmHg at the higher dose in the same 80 adults. The written rule grades by use: one positive randomized trial is C, and a tested harm is D Route 2, so each result gets its row. The headline keeps the harm finding, since a record whose only trial raised LDL in people enrolled for high cholesterol should lead with that. Boron's Route 2 (two null marker trials) is confirmed on the same rule without change. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
Correction5-HTP: C confirmed under the written rule
Record5-htp
What happenedDepressive symptoms rest on randomized evidence that is thin: a Cochrane review that could pool two small trials and called the result inconclusive (Shaw et al., 2002; PMID 11869656), a weak pooled analysis (Javelle et al., Nutr Rev, 2020; PMID 31504850) and two small trials (Jangid et al., 2013; PMID 23380314; Meloni et al., 2020; PMID 32067288). The written C is exactly this: human randomized evidence that exists but is thin. D would require that the depression trials were null, which they were not; the null trial (Truyens et al., Gastroenterology, 2022; PMID 35940251) was in fatigue and carries that use's D Route 2. Review closed. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionAkkermansia muciniphila: insulin sensitivity to D Route 2, weight regain its own use at C, headline C
Recordakkermansia
What happenedThe record held C on a positive pilot (Depommier et al., Nat Med, 2019; PMID 31263284) whose 142-person scale-up (Suenaert et al., Gut Microbes, 2026; PMID 42343233) missed its primary endpoint, with a second trial null between groups (Zhang et al., Cell Metab, 2025; PMID 39879980). Under the written rule a use tested without benefit is D Route 2, whatever the pilot said. The weight-regain trial (Mount et al., Nat Med, 2026; PMID 42120725) is a different endpoint in a different population, one positive randomized trial run by the maker: C on its own row with the funding stated beside the letter. The headline follows the best use and stays C. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionSAM-e: grade reading rewritten to the C the record holds; review closed by the written rule
Recordsam-e
What happenedThe headline moved D to C in October to follow the monotherapy use, and the grade reading still opened 'Grade D on Route 2', so the page argued for a letter it did not carry. The reading now states the C: pooled analyses of randomized trials disagree (Limveeraprajak et al., 2024, PMID 38423354, positive; Galizia et al., Cochrane, 2016, PMID 27727432, and Peng et al., 2024, PMID 38199136, null), which is mixed randomized evidence and C by definition; the add-on and osteoarthritis uses stay D Route 2 on null trials. The 'editor to confirm C or hold D' review is closed: Route 2 requires that the trials showed no benefit, and one moderate-certainty pooling says they did. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionNMN: blood NAD+Nicotinamide adenine dinucleotide, a molecule cells use in energy metabolism. Its level falls with age in some tissues. use confirmed at B by the written rule; review closed
Recordnmn
What happenedThe use rose C to B in October on four randomized trials that agree on higher blood NAD+ (PMIDs 36482258, 36740954, 38789831, 36797393), every one run or funded by an NMN maker, which the replication funding rule of September counts as replication and states beside the letter. Replicated randomized evidence on a surrogate is B, and the surrogate is what keeps it from A; a blood level is not a health outcome, which the record states. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
Corrected October 2026
CorrectionTaurine: endothelial-marker use confirmed at B and glycemic use at C by the written rule; review closed
Recordtaurine
What happenedThe endothelial and inflammatory marker use in type 2 diabetes rose C to B in October on three randomized trials (PMIDs 35870947, 32015761, 40546935) plus a 2026 pooled analysis; replicated randomized evidence on surrogates is B. The review noted that two trials are Iranian academic trials whose Tabriz cohorts may overlap; independence of groups is the A requirement, not the B one, and the record states the overlap. The glycemic use is C on one null and two positive trials (PMIDs 35870947, 32472292, 32861603), mixed by definition. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
Corrected October 2026
CorrectionL-citrulline: blood pressure and exercise performance graded on their own rows; blood pressure C, performance D Route 2
Recordcitrulline
What happenedThe headline C covered a borderline blood-pressure result and a performance claim the pooled trials do not support. Graded by use: blood pressure rests on two pooled analyses that disagree (Barkhidarian et al., 2019; PMID 30788274; Mirenayat et al., 2018; PMID 30284051), mixed, C; aerobic and endurance performance of free L-citrulline rests on two pooled nulls (Viribay et al., 2022; PMID 36079738; Harnden et al., 2023; PMID 37155582), D on Route 2, with the citrulline malate strength findings (Trexler et al., 2019; PMID 30895562; Wang et al., 2026; PMID 42356270) stated as a different form. Headline unchanged at C. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionCold-water immersion: attenuated strength gains after resistance training graded as a tested harm; not-replicated flag removed
Recordcold-water-immersion
What happenedThe record described in prose that immersion after lifting blunted strength and muscle gains (Roberts et al., J Physiol, 2015; PMID 26174323) and that two pooled analyses agree (Malta et al., Sports Med, 2021; PMID 33146851; Grgic, Eur J Sport Sci, 2023; PMID 35068365), but carried no row for it. Under the written rule a treated arm that did worse than control on the stated endpoint is D on Route 2 with the harm badge, so the finding now has its own row where a reader meets it. The headline C rests on the Cain 2025 pooling (PMID 39879231) and the Buijze 2016 trial (PMID 27631616), pooled randomized evidence, so the not-replicated flag contradicted the record and is removed; the letter is unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionBacopa protocol renamed to the standardized extract dose the pooled trials used; C unchanged
Recordbacopa-monnieri-600-mg-55-bacosides
What happenedThe protocol was named for 600 mg or more at 55 percent bacosides. The pooled chronic trials (Kongkeaw et al., J Ethnopharmacol, 2014; PMID 24252493; 9 trials) used 300 to 450 mg/day, the only chronic 600 mg trial (Peth-Nui et al., 2012; PMID 23320031) used a 5 percent saponin extract, and the 600 mg advantage in Tiemtad et al. (Phytomedicine, 2026; PMID 41678913) is an indirect network comparison. The written B and C attach to the dose and form the trials used, so the name now reads Bacopa monnieri standardized extract 300 to 450 mg/day. The letter stays C: pooled gains on two measures against a null 2025 trial of 300 mg (Lopresti et al., 2025; PMID 41091332) is mixed evidence. The three options on the decision sheet collapse to this one under the rule. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionKetogenic diet: epilepsy use confirmed at B by the written rule; headline stays C
Recordketogenic-diet
What happenedThe decision sheet asked whether drug-resistant epilepsy in children should be A. Two independent randomized trials (Neal et al., Lancet Neurol, 2008; PMID 18456557; Lambrechts et al., Acta Neurol Scand, 2017; PMID 27027847) and a Cochrane pooling (Martin-McGill et al., 2020; PMID 32588435) agree on fewer seizures, but seizure counts come from unblinded diaries kept by families, and the written A admits three endpoint kinds only: a hard clinical event, an instrument reading, or a scale scored by a blinded clinician. A diary in an unblinded trial is none of these, so the use is B at the self-report ceiling. The headline stays C on the longevity question: a use in children with drug-resistant epilepsy does not lift the headline of a record read by adults asking about diet and aging, and the record says so. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionCarnosine: C confirmed on the glycemic use by the written rule; review closed
Recordcarnosine
What happenedThe October split left the editor to confirm: glycemic markers in prediabetes or type 2 diabetes at C on small mixed trials (Houjeghani et al., 2018; PMID 29420997; Hariharan et al., 2024; PMID 38172006; Peng et al., 2020; PMID 31987255), musculoskeletal measures at D Route 2 on null trials (Saadati et al., 2024; PMID 39770949; O'Toole et al., 2026; PMID 42308284). Small positive trials with high heterogeneityHow much the results of the pooled trials differ from each other. High heterogeneity makes a combined estimate less reliable. and no effect on fasting glucose or insulin resistance in the pooled data is thin randomized evidence, which is C by definition; tested without benefit is D Route 2 by definition. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionCordyceps: the 2025 pooled trials identified from the full text; C confirmed; review closed
Recordcordyceps
What happenedThe review of October asked that the trials pooled by Shu et al. (Front Nutr, 2025; PMID 41280379) be identified before the letter moved. The full text names them: the Cordyceps sinensis pools for VO2peak and ventilatory threshold rest on Parcell et al. (Int J Sport Nutr Exerc Metab, 2004; PMID 15118196), null; a 2021 Thai crossover in 12 runners, rated high risk of bias by the reviewers and published in a journal PubMed does not index, positive on VO2max; and a 2022 Brazilian marathoner trial, also unindexed, with no VO2max change. The pooled VO2peak gain is carried by the one high-risk trial. Two named null trials on VO2max, one positive small trial, and a threshold gain in older adults (Chen et al., 2010; PMID 20804368) is thin, mixed randomized evidence: C, unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionL-tyrosine: the stress-marker null stated, the dose gap stated, two heat-stress nulls and an older-adult harm signal added
Recordl-tyrosine
What happenedThe record named acute stress as its endpoint while the cited trial (McAllister et al., Stress, 2024; PMID 38975711) found no effect on any stress marker and a single positive Stroop count. The endpoint is now working memory and reaction measures under acute stress, which is what the positive trials measured: Mahoney et al. (Physiol Behav, 2007; PMID 17585971) in cold and Deijen et al. (Brain Res Bull, 1999; PMID 10230711) in combat training. Two heat-stress trials were null (Coull et al., 2016; PMID 26285023; Donnan et al., 2025; PMID 39820592), and van de Rest et al. (Nutrients, 2017; PMID 29168741) found working memory declining with dose in adults aged 60 to 75, now in the caution. No dose was stated; the trial doses are, and they are far above a capsule. C unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionLactoferrin: the maker's second trial and two independent nulls added; infection prevention in adults graded D Route 2 on its own row
Recordlactoferrin
What happenedThe record rested on one maker-run trial and called it the only adult trial. The same maker's larger trial (Oda et al., J Microbiol Immunol Infect, 2021; PMID 32151562; 310 adults) shortened illness by about a day and found no difference in how many people got sick; an independent 90-day trial in health workers (Navarro et al., Biometals, 2023; PMID 36474100) found no reduction in SARS-CoV-2 infection; and the pooled adult odds ratio for respiratory infection is 1.00 (Berthon et al., Adv Nutr, 2022; PMID 35481594). Graded by use: symptom scores C on the maker's trials, with the funding stated; infection prevention in adults D on Route 2. The 2023 trial's full analysis set and dropout imbalance are now stated. Headline unchanged at C. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionLion's mane protocol: the lead author's commercial affiliation stated, the second trial and the healthy-adult nulls added
Recordlion-s-mane-1-000-mg-fruiting-body
What happenedThe protocol, already renamed to the studied 3 g/day, cited Mori et al. (Phytotherapy Research, 2009; PMID 18844328) alone and said nothing about the lead author's affiliation with a commercial mushroom producer, now stated beside the letter. Added: Saitsu et al. (Biomedical Research, 2019; PMID 31413233), one of three cognitive tests improved in healthy older adults at a dose the abstract does not state; Li et al. (Front Aging Neurosci, 2020; PMID 32581767), the only chronic trial near 1,000 mg/day, which used erinacine-enriched mycelium in mild Alzheimer's disease; and three null or mostly null trials in healthy young adults (Grozier et al., 2022; PMID 36582308; Docherty et al., 2023; PMID 38004235; Surendran et al., 2025; PMID 40276537). C unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionLion's mane: endpoint retyped to measured cognitive tests, unsupported uses removed, the dose stated as studied, nulls and safety added
Recordlions-mane
What happenedThe record typed its endpoint as self-report and called measured cognitive tests surrogates; Mori et al. (Phytotherapy Research, 2009; PMID 18844328) used a clinician-administered scale and Saitsu et al. (Biomedical Research, 2019; PMID 31413233) measured tests, which are functional outcomes under the written rule, so the type is corrected. Saitsu is restated as partial: one of three tests improved. The best-use line listed nerve growth factor, neuroplasticity, mood and nerve support, none of which any cited trial measured; it now names what was measured. The dose line led with 500 to 1,000 mg of extract, which no positive trial used; it now states the 3 g/day of powder the trial gave. Added: three null or mostly null trials in healthy young adults (PMIDs 36582308, 38004235, 40276537), the mycelium trial as a different form (Li et al., 2020; PMID 32581767) with its withdrawals for stomach discomfort, nausea and rash now in the caution, the 2025 systematic review (Menon et al., Front Nutr, 2025; PMID 40959699), and the lead author's commercial affiliation beside the letter. C unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionLow-dose naltrexone: the larger null trials in both indications added, pilots and the glioma null relabeled, the patent disclosed; C by use
Recordlow-dose-naltrexone
What happenedThe record held C on two pilots presented as trials, one small positive crossover, one patent-holders' Crohn's trial and a null glioma trial listed as if supportive. Three larger fibromyalgia trials were null on pain (Bested et al., Pain Rep, 2023; PMID 38226027; Due Bruun et al., Lancet Rheumatol, 2024; PMID 38258677; Rodriguez-Freire et al., Eur J Pain, 2026; PMID 42385209), the independent Crohn's trial was stopped for futility (van de Pol et al., Dig Dis Sci, 2026; PMID 42701992), the Cochrane review found clinical remission not significant (Parker et al., 2018; PMID 29607497), and the 2025 pooled analysis (Hegde et al., PMID 40540205) found more adverse events than placebo. Smith et al. 2007 (PMID 17222320) and Younger and Mackey 2009 (PMID 19453963) are relabeled as pilots, Peters et al. 2022 (PMID 35001215) as null, and the narrative review (Li et al., Int Immunopharmacol, 2018; PMID 29885638) is removed from the grade support. The Smith and Zagon patent (PMID 21380937) is stated beside the Crohn's letter. Both indications are C under the rule's own words, a replication that failed; the headline stays C. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionLuteolin: olfactory endpoint retyped as measured performance, the combination's own nulls added, the luteolin-alone null graded on its own row
Recordluteolin
What happenedThe record's D Route 1 for the olfactory use stands: every olfactory trial tested palmitoylethanolamide plus luteolin, and a combination does not grade one ingredient. Three corrections: smell tests are measured performance, not surrogates, so the endpoint type is functional; the combination's own evidence is mixed, with the independent Dresden trial finding no difference in clinically meaningful improvement (Gellrich et al., ORL, 2024; PMID 38861957) and the four-arm trial finding the combination without training no better than training with placebo (Di Stadio et al., 2023; PMID 37380908); and the one luteolin-alone placebo-controlled trial (Hodgin et al., 2021; PMID 33802381), null for Gulf War illness symptoms, is a tested null, D on Route 2 on its own row, not an absence. The search note that said all 14 records were combination products is corrected. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionMagnesium glycinate, insulin resistance: the review relabeled as narrative, the 2026 null meta-analysis and two poolings added; D Route 1 unchanged
Recordmagnesium-glycinate-300-400-mg
What happenedThe description said magnesium improved insulin resistance in humans on the strength of Morais et al. (Nutrition, 2017; PMID 28526383), a narrative review of 12 trials of other salts whose own conclusion limits benefit to magnesium-deficient, insulin-resistant people. Added: Amiri et al. (BMC Nutr, 2026; PMID 42426860), 15 trials in diabetes and prediabetes, no significant change in insulin or HOMA-IR; Simental-Mendia et al. (Pharmacol Res, 2016; PMID 27329332) and Mohammadi et al. (Nutrients, 2026; PMID 42588058), modest HOMA-IR reductions. The glycinate form remains untested on this endpoint, so D Route 1 stands; the reading now says the class evidence would be C, not B. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionMagnesium glycinate for sleep: renamed to the one glycinate trial's 250 mg dose; the trial, two nulls and the 2026 review added; mechanism claim removed
Recordmagnesium-glycinate-300-400-mg-at-bedtime
What happenedThe record claimed multiple randomized trials improved sleep onset while citing one pooled analysis of three small trials of other salts (Mah et al., 2021; PMID 33865376), asserted a GABA and melatonin mechanism as settled, and carried a not-replicated flag beside pooled evidence. The one randomized trial of the glycinate form (Schuster et al., Nat Sci Sleep, 2025; PMID 40918053; 155 adults, 250 mg elemental, borderline positive on insomnia severity) is now the basis, with its glycine co-dose stated; the null citrate trial (Nielsen et al., 2010; PMID 21199787), the positive older-adult trial (Abbasi et al., 2012; PMID 23853635) and the 2026 systematic review concluding the evidence does not support magnesium for insomnia (Lopresti et al., 2026; PMID 42661485) are added. The written letter attaches to the dose and form studied, so the name moves from 300 to 400 mg to the 250 mg that was tested. C unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionMagnesium glycinate, blood pressure: the 2025 meta-analysis added, uncited deficiency claims removed; D Route 1 unchanged
Recordmagnesium-glycinate-300-400-mg-elemental
What happenedThe description presented about 2 mmHg as a general effect and carried two uncited claims (deficiency is common; red-cell magnesium is the more sensitive measure). Argeros et al. (Hypertension, 2025; PMID 41000008), 38 trials, is added: no significant effect in people with normal blood pressure, falls of 7.7 and 6.0 mmHg in treated hypertensives and people with low magnesium, no dose-response. The glycinate form remains untested on blood pressure, so D Route 1 stands; the reading says the class evidence would be B in hypertensive or magnesium-depleted adults and not in normotensive ones. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionMBSR: trial count corrected, the pooled analysis restated as programs generally, two independent poolings and the blinded trial added, uncited claims removed
What happenedThe description said a 32-trial meta-analysis; Goyal et al. (JAMA Intern Med, 2014; PMID 24395196) pooled 47 trials of mindfulness meditation programs generally, not MBSR alone, found only low-strength evidence for stress, did not assess rumination or emotional regulation, and found no superiority over active treatments, none of which the record said. The uncited claim that apps have smaller effects than instructor-led MBSR is removed. Added: Khoury et al. (J Psychosom Res, 2015; PMID 25818837), 29 MBSR studies in healthy adults; Galante et al. (PLoS Med, 2021; PMID 33428616), 136 trials, with its null against specific active controls; and the TAME trial (Hoge et al., JAMA Psychiatry, 2023; PMID 36350591), MBSR noninferior to escitalopram on a blinded clinician scale. Replicated pooled self-report evidence is B, unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionLow-dose melatonin protocol: renamed to the studied 0.3 to 0.5 mg and 30 to 60 minutes, the 90-minute and low-equals-high claims removed, nulls and a glucose caution added
What happenedThe protocol named 0.5 to 1 mg at 90 minutes before sleep and said a low dose was as effective as a high one. No trial tested that dose range at that lead time; the low-dose trials used 0.3 mg at 30 minutes (Zhdanova et al., 2001; PMID 11600532) and 0.5 mg at one hour (Sletten et al., 2018; PMID 29912983), and the dose-response evidence runs the other way (Cruz-Sanabria et al., 2024; PMID 38888087; Herxheimer and Petrie, 2002; PMID 12076414). The name now states the studied dose and timing, in the pattern already applied to other protocols. The endpoint type is corrected to measured function, since the trials used polysomnography and actigraphy. Added: the adult-only insomnia null (Choi et al., 2022; PMID 36179487) and the glucose-tolerance signal at 5 mg (Qian et al., 2026; PMID 42346809). C unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionMesenchymal stem cells: the graded product named in the title, the umbilical cord trials and the 2026 systematic review added as non-replicating context, Tompkins relabeled
Recordmsc-therapy
What happenedThe record's title covered allogeneic intravenous MSCs in general while its grade rests on one developer's bone marrow-derived product, so the title now says so. The grade basis said nothing had replicated Ruiz 2026 (PMID 41747733); it now names the open-label umbilical cord trial (Nguyen et al., EBioMedicine, 2026; PMID 42019090) and the Zhu 2024 secondary outcomes (PMID 38679727) and explains why a different product in an unblinded design does not count, with the systematic review that could not pool the three trials (Poutouri et al., 2026; PMID 42737497). Tompkins 2017 (PMID 28977399) is relabeled: safety primary, walk gain in one dose arm only. C unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionMilk thistle: the 2025 Cochrane review and two null biopsy trials added, the 2024 meta-analysis relabeled, form and dose scope stated
Recordmilk-thistle
What happenedThe record cited two meta-analyses and no trial. Added: the 2025 Cochrane review (Wang et al., PMID 40552569), which rates the ALT benefit very low certainty and finds silymarin complexes no better than placebo; the NIH-funded phase II trial null on histology at 420 and 700 mg three times daily (Navarro et al., 2019; PMID 31536511); and the Malaysian biopsy trial whose primary endpoint was not met (Wah Kheong et al., 2017; PMID 28419855). Li et al. (2024; PMID 38579127) is relabeled: it pools complexes and combination products with plain silymarin, its histology claim conflicts with the biopsy trials, and its enzyme effect sizesHow large a difference the treatment made, as distinct from whether the difference could be detected at all. are implausible as labeled. The best-use line now says which form and dose range were tested and that complexes are different agents. C unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
What happenedThe description still said sleep outcomes were not graded here and cited only Goyal et al. (2014; PMID 24395196), while the grade basis had been rebuilt on the sleep meta-analyses (Rusch et al., 2019; PMID 30575050; Chen et al., 2020; PMID 32590218) and the randomized trials (Black et al., 2015; PMID 25686304; Ong et al., 2014; PMID 25142566; Perini et al., 2023; PMID 34193328). The description now matches: B on self-reported sleep quality, no difference from specific active treatments. The name said 20 minutes a day self-guided, a dose and format no cited trial tested; in the pattern applied to other protocols it now names the weekly group course with home practice the trials used. B unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionHydrogen water: the lipid endpoint now rests on three meta-analyses, the original citation relabeled as null for lipids, maker funding stated
Recordhydrogen-water
What happenedThe record's only citation (Zanini et al., 2021; PMID 34601077) was a 40-person pilot that found no lipid or metabolic difference, while the evidence note claimed multiple positive trials and the flags claimed a meta-analysis nobody cited. The lipid claim now rests on the three meta-analyses that exist and disagree (Ye et al., 2026; PMID 41888952; Jamialahmadi et al., 2024; PMID 39839806; Todorovic et al., 2023; PMID 37259294), with the key 24-week trial's part-funding by the tablet maker and its lead author's industry consultancy stated beside the letter (LeBaron et al., 2020; PMID 32273740). Zanini 2021 is relabeled as a pilot null on the graded endpoint. C unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionMulti-cancer early detection test: the stage IV secondary stated as a nonsignificant trend, the endpoint typed as a surrogate, the AHRQ review and the UK screening committee statement added
Recordmced-blood-test
What happenedThe grade basis said stage IV alone improved; the rate ratio was 0.86 with a confidence intervalThe range the true effect probably falls in. A wide interval means the estimate is uncertain. reaching 1.00 (Sasieni et al., NEJM, 2026; PMID 42776074), a trend, not a demonstrated improvement, and the text now says so. Late-stage incidence is a stage-shift surrogate for cancer mortality, so the endpoint type is corrected from hard to surrogate, with the UK National Screening Committee position statement cited (Batson et al., BMJ, 2026; PMID 42185047). The Mann 2026 spillover analysis (PMID 42217468) now states its result, a transient rise in diagnostic delay the authors judged immaterial, and is labeled observational. The AHRQ systematic review (Kahwati et al., Ann Intern Med, 2025; PMID 40953446), which found no completed controlled study showing screening benefit, is added. D Route 2 unchanged; funding disclosure retained. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionMulti-domain lifestyle protocol: renamed to the studied program, the supplements in the intervention and the men-only population stated, the reversal claim restated as a between-group difference, corrections and the case series added
What happenedThe description said one trial reported reversal of an epigenetic clockA test that estimates biological age from chemical marks on DNA (DNA methylation).. The trial (Fitzgerald et al., Aging, 2021; PMID 33844651) randomized 43 men aged 50 to 72 to a program that included two supplements from the funder; the within-group change was not significant (p=0.066) and only the between-group difference was (p=0.018), so reversal overstated it. The record now names the clock (the 2013 Horvath clock, in saliva), the population, the supplements, the two published corrections (PMID 35907207, PMID 38488762) and the authors' uncontrolled case series in six women (PMID 36947707), which is not a replication. The track field, which described a FINGER-style cognitive battery the trial never measured, now follows the trial's own endpoint. In the pattern applied to other protocols the name states what was studied. C unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionOral NAD+: the record no longer says no human trial exists; the 2026 pharmacokinetic trial is cited with its developer links, the 2026 systematic review added, the absence record re-run
Recordnad-direct
What happenedThe best-use line and ref said intact oral NAD+ had no controlled human trial while the form note described one. The one randomized trial (Kornilov et al., GeroScience, 2026; PMID 42530810) is a 5-day pharmacokinetic study of a proprietary formulation whose authors are linked to its developer; it raised whole-blood intracellular NAD and left plasma NAD unchanged, and measured no outcome. The record now says no randomized trial has tested oral NAD+ on any health outcome, cites the 2026 systematic review that found none for oral or intravenous NAD+ (Gallagher et al., Aging Res Rev, 2026; PMID 41655607), corrects the preclinical-only flags, and notes that NADH trials are a different form in combination. D Route 1 unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionNMES after knee replacement: the replication block corrected and completed, the device-maker funding named, as-studied dose and duration stated as heterogeneous, Avramidis and DeJong relabeled, three trials added
Recordnmes-knee-replacement
What happenedThe replication block listed the Cleveland trial (Klika et al., 2022; PMID 32610358) as unclear funding when the report states funding by Cymedica Orthopaedics, the device maker, now stated; and it omitted the cleaner independent replication on dynamometer strength, Yoshida et al. (2017; PMID 28610968), now listed. The as-studied dose and duration fit the Colorado trial only and now state the three trials' differing regimens. Avramidis 2011 (PMID 21410130) is relabeled as vastus medialis stimulation with mobility and self-report outcomes, and DeJong 2020 (PMID 32360105) as patterned stimulation, a different form. Added: Levine 2013 (PMID 23464951), home stimulation noninferior to supervised therapy; Cheuy 2023 (PMID 35856287), same Colorado group; Monaghan 2010 Cochrane (PMID 20091621) as context. The letter stays A: instrument-measured strength replicated by independent groups is what the written A asks for; the basis now states the case for B so the editor can weigh it. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionExtended-release niacin: laropiprant named, AIM-HIGH added as the clean null, the badge restated as no benefit with a harm signal, Cochrane and the Coronary Drug Project added
Recordniacin-supplemental
What happenedThe record described HPS2-THRIVE (Landray et al., NEJM, 2014; PMID 25014686) as extended-release niacin and badged it harm found; the trial gave niacin combined with laropiprant in one pill, so its excess serious adverse events (Haynes et al., 2019; PMID 31447131) cannot be assigned to niacin alone. The large trial of extended-release niacin alone on a statin, AIM-HIGH (Boden et al., NEJM, 2011; PMID 22085343), was missing and is now the record's clean test, null. The badge reads TESTED, NO BENEFIT with the combination trial's harm signal stated in the certainty line, the title and the basis. Added: the Cochrane review of 23 trials with no effect on death, infarction or stroke (Schandelmaier et al., 2017; PMID 28616955), both trials' maker co-funding, the run-in that excluded niacin-intolerant people, and the Coronary Drug Project (Canner et al., J Am Coll Cardiol, 1986; PMID 3782631) as the reason immediate-release niacin is excluded rather than graded. D Route 2 unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionNMN: the blood-pressure meta-analysis described and moved off the Route 1 row, the null insulin-sensitivity trial and three null meta-analyses added, the sublingual and liposomal claims corrected
Recordnmn
What happenedText corrections after the letters were set earlier today. The Route 1 longevity row cited a blood-pressure meta-analysis (Zhang et al., 2026; PMID 41901064), which now sits in the ref described as what it is: diastolic pressure about 2 mmHg lower, systolic unchanged. The insulin-sensitivity row omitted the one other direct measurement, null at 2,000 mg/day (Pencina et al., 2023; PMID 36740954), and three meta-analyses finding no effect on glucose, insulin, HbA1c or HOMA-IR (PMIDs 39531138, 39116016, 42514320), now stated. The dose line said sublingual may improve absorption; the only randomized comparison (Wakabayashi et al., 2026; PMID 42304075) found no NAD+ difference between routes. The liposomal claim had no trial and is removed. The industry authorship of Yi 2023 (PMID 36482258) is stated. Letters unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionOmega-3 2 to 4 g/day protocol: REDUCE-IT demoted from the lead and its funding and placebo stated, the atrial fibrillation signal added, Cochrane's nulls stated, the Omega-3 IndexThe share of EPA and DHA among the fatty acids in red blood cell membranes, reported as a percentage. target labeled observational, PISCES added
What happenedThe description led with REDUCE-IT's 25 percent reduction (Bhatt et al., NEJM, 2019; PMID 30415628), which tested purified EPA, a different agent, in a trial funded by its maker against a mineral-oil placebo; it now leads with the null trials at the protocol's dose, STRENGTH (Nicholls et al., JAMA, 2020; PMID 33190147) and OMEMI (Kalstad et al., Circulation, 2021; PMID 33191772). Added: the dose-related atrial fibrillation increase in the outcome trials (Gencer et al., 2021; PMID 34612056; Abuknesha et al., 2026; PMID 42517224), the most relevant harm at 2 to 4 g/day, and OMEMI's own borderline signal; the Cochrane review's high-certainty nulls on mortality and cardiovascular events (PMID 32114706) beside the slight coronary death reduction the record quoted; the population-specific positive PISCES trial in hemodialysis (Lok et al., NEJM, 2026; PMID 41201837); and the fact that Hu 2019 (PMID 31567003) pooled trials mostly at 1 g/day or less. The Omega-3 Index target and the form line are restated as untested. The not-replicated flag, inconsistent with the record, is removed, and the name loses its dash. C unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionPanax ginseng: the Cochrane finding restated as a trivial effect, the studied form and dose named on the use row, the herbal meta-analysis and the crossover trial added, the safety line and the unsupported track field corrected
Recordginseng
What happenedThe ref said the Cochrane review (Lee et al., 2021; PMID 33871063) showed possible benefit; it found a statistically significantUnlikely to be explained by chance alone at the threshold the study set. It says nothing about whether the difference is large enough to matter. but trivial gain on erectile function scales, below the minimal clinically important difference, with only self-reported ability to have intercourse improved at low certainty, and the record now says so. The record named no form, dose or duration; the use row states Korean red ginseng or ginseng berry extract at about 600 to 2,700 mg/day for 4 to 12 weeks, with Hong et al. (2002; PMID 12394711) as the representative trial. Added: the 2026 herbal-supplement meta-analysis (Ho et al., PMID 41696741) and the Cochrane adverse-event finding. The vague endpoint and the track field's fatigue, immune and cognitive applications, none graded, are replaced. C unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionPEMF protocol: the longevity framing and the fracture 'solid evidence' claim removed, the null osteoarthritis meta-analyses added, renamed to the graded use
Recordpemf-pulsed-electromagnetic-field
What happenedThe description graded a consumer longevity application on an osteoarthritis meta-analysis and called fracture non-union evidence solid. No randomized trial of PEMF on a longevity, aging or hard outcome exists, and the Cochrane review of non-union (Griffin et al., 2011; PMID 21491410) found the pooled effect not significant, with a 2024 update (Picelli et al., PMID 39387850) not supporting PEMF for acute fractures. Added beside Wu 2018 (PMID 30552258): the null pain results of Chen et al. (2019; PMID 31583420) and Chang et al. (2026; PMID 42075549). The not-replicated flag, wrong for a 12-trial meta-analysis, is replaced; the evidence is mixed, not unreplicated. The name now states the graded use. C unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionPiperlongumine: the mechanism corrected to what the cited paper reports, the animal claim removed, the authors' patent and company ties stated
Recordpiperlongumine
What happenedThe record said piperlongumine kills senescent cells by pushing reactive oxygen species past a threshold, shown in cells and animals. The one cited paper (Wang et al., Aging, 2016; PMID 27913811) reports apoptosis in cultured fibroblasts that did not require reactive oxygen species, and its abstract reports no animal work. Its authors' patent application and senolyticA compound intended to clear senescent cells: older cells that have stopped dividing but remain in tissue. company ties are now stated. The advice-shaped sentence in the form note is replaced with a description. D Route 1 unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionPower training protocol: renamed to the studied comparison, the two further head-to-head reviews added, the plyometric examples and uncited claims removed
Recordplyometric-and-power-training
What happenedThe record was named plyometric and power training and listed box jumps and medicine ball throws, but its one citation (Balachandran et al., JAMA Netw Open, 2022; PMID 35544136) pooled fast-velocity resistance training against traditional lifting, mostly on machines, and found a small low-certainty advantage with self-reported function null. Added: Morrison et al. (2023; PMID 37328359), which calls the effects similar, and the Lopez et al. network meta-analysis (2023; PMID 36378500), which finds traditional training better on two tests; jump training in older adults (Moran et al., 2018; PMID 30341594) is cited as a power outcome, not function. The uncited opening claim about power declining faster than strength is removed, and the track field now names the tests the trials used. C unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionProcyanidin C1: the one-mouse-study claim updated, the mechanism restated as the cited paper gives it, the founding study's funding and patent interests stated
Recordprocyanidin-c1
What happenedThe record said the evidence was one mouse study acting on BCL-2 pathways. Later mouse work from other groups exists (Liu et al., PNAS, 2024; PMID 38657052), and the founding paper (Xu et al., Nature Metabolism, 2021; PMID 34873338) describes reactive oxygen species and mitochondrial dysfunction, not BCL-2; its supplement-company funding and the authors' patent and senolytic company interests are now stated beside the Expression of Concern (PMID 41731120). D Route 1 unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionPsyllium protocol: the psyllium-specific meta-analysis and the 2025 update added, the effect size stated, the Plantago pool relabeled, tolerability and spacing from medicines added
Recordpsyllium-husk-10-to-15-g-day-for-ldl-c
What happenedThe B rested on a Plantago-genus pool (Zhu et al., Nutr Res, 2024; PMID 38688104) and gave no effect size. The psyllium-specific meta-analysis at the protocol's dose (Jovanovski et al., Am J Clin Nutr, 2018; PMID 30239559), the 2025 update (Gholami et al., PMID 41366295) and a representative 26-week trial (Anderson et al., 2000; PMID 10837282) are added, with the pooled LDL reduction of about 0.33 mmol/L stated. Zhu 2024 is relabeled as a genus-level pool whose 7 percent risk figure is a projection. Tolerability and the spacing of psyllium from other oral medicines are added. B unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionPterostilbene: the unsourced bioavailabilityThe share of a dose that reaches the bloodstream in a form the body can use. and blood-brain barrier claims removed, the companion safety report and two later trials added
Recordpterostilbene
What happenedThe dose line quoted an 80 percent against under 1 percent bioavailability comparison with resveratrol and the form note a blood-brain barrier advantage; neither has a human study on the record, and both are restated as unsupported. Added as context to the D Route 2 set in October: the safety report from the same trial (Riche et al., J Toxicol, 2013; PMID 23431291), a 12-week safety pilot with no efficacy outcome (Otsuka et al., 2025; PMID 40024751) and a megestrol combination trial in endometrial cancer with a null primary (Senguttuvan et al., 2025; PMID 40227411). Letters unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionPEMF device: the cited meta-analysis restated as null on its primary outcomes, the positive and null syntheses and the 2026 sham trial added
Recordpemf
What happenedThe record summarized Chang et al. (2026; PMID 42075549) as modest self-reported benefit when its headline result is no VAS pain or total WOMAC improvement at one month, no objective function change and high risk of bias; it is now described as such. The evidence note claimed significant pain effects while Chen et al. (2019; PMID 31583420) found none. Added: the positive syntheses (Wu et al., 2018; PMID 30552258; Yang et al., 2020; PMID 32251502; Vigano et al., 2021; PMID 32508140) so the mixed picture is visible, and the 2026 double-blind sham trial null on WOMAC and function (Lau et al., PMID 41588476). The not-replicated flag, wrong for a nine-trial pool, is replaced: the problem is inconsistency. C unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionRapamycin: the third null randomized trial added, the daily-dosing statement corrected, the Kell 2026 marker study restated, the prescribing company's role in PEARL stated
Recordrapamycin
What happenedThe record said rapamycin had been given to humans twice on aging questions and that no trial had tested daily dosing. Kraig et al. (Exp Gerontol, 2018; PMID 29408453) randomized 25 adults aged 70 to 95 to 1 mg daily and found no change in cognition, grip strength or walking, with falls in hemoglobin and red cell indices; it is now the third tested-null payload and its safety signal is in the cautions. The Kell 2026 study (PMID 41524558) is restated as a 4-against-5 marker study reporting lower immune-cell p21, not a white-cell-count study. The best-use line no longer says one trial found attenuation of exercise benefit, which the basis itself discounts. PEARL's support by the telehealth company that prescribes rapamycin, with authors employed there, is stated. D Route 2 unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionRed yeast rice: the primary endpoint named and mortality marked secondary, the recycled meta-analyses explained, statin-class safety and the pooled safety data added
Recordred-yeast-rice
What happenedThe endpoint and ref read recurrent coronary events and mortality as if equal; CCSPS (Lu et al., Am J Cardiol, 2008; PMID 18549841) pre-specified major coronary events and reported mortality as secondary, which the record now says. The meta-analysis of post-infarction patients (Sungthong et al., Sci Rep, 2020; PMID 32066811) is cited with the note that it counts CCSPS subgroup papers as separate studies, so it is not replication. Safety now states the statin-class risks of monacolin K, the pooled randomized safety data (Fogacci et al., 2019; PMID 30844537) and the umbrella review's uric acid and liver enzyme signals (Ma et al., 2024; PMID 38413255). The trial's funder is stated as not given in the indexed record. C unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionAnticholinergic deprescribingReducing or stopping a medication under a prescriber's supervision.: the null trials named, the endpoint retyped, the cardiovascular outcome marked untested, the observational signal stated as ungraded
Recordreducing-anticholinergic-drug-burden
What happenedThe D Route 2 rested on two pooled analyses without naming a trial. Added: Kersten et al. (J Gerontol A, 2013; PMID 22982689), the one trial that clearly lowered the burden, null on cognition at 8 weeks, and van der Meer et al. (BMJ Open, 2018; PMID 30030308), which did not lower the burden and found no difference in falls, admissions or mortality. The endpoint type is corrected to the measured cognition and function outcomes the trials used; cardiovascular events, the only hard outcome the observational study links to burden, are marked as never tested. The sentence calling the observational harm signal real is replaced: association carries no grade in either direction. The track field no longer tells the reader what to do. D Route 2 unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionResistance training: the Cochrane review added to the A, the second HbA1c meta-analysis and the earlier blood pressure pool added, the strength wording matched to what moved, one replication funder marked unclear
Recordresistance-training-2-3-week
What happenedThe A rested on one pooled analysis in adults 75 and over; the Cochrane review of progressive resistance training (Liu and Latham, 2009; PMID 19588334), 73 trials on measured strength, now stands beside it and the population is no longer narrowed to 75 and over. The glycemic use said it rested on a single pooled analysis; Wan et al. (2024; PMID 38623887), 46 trials, is added. The blood pressure use now cites the earlier, smaller Cornelissen pool (2013; PMID 23525435). Wording that implied every measure improved is corrected: handgrip strength and fiber size did not change significantly in Grgic 2020 (PMID 32740889). The Greek replication trial (Kalapotharakos et al., Aging Clin Exp Res, 2010; PMID 20440099) states no funder, so its entry reads unclear. Letters unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionRhodiola: the independent trial that found fatigue worse on Rhodiola added, the two systematic reviews added, the AMPK and anti-aging claims and the untested dose range removed
Recordrhodiola
What happenedThe record cited four small trials of one proprietary extract, each with a maker-linked author, and omitted the only fully independent registered trial (Punja et al., PLoS One, 2014; PMID 25268730), in which fatigue was significantly worse on Rhodiola than on placebo. Added with it: the systematic reviews rating every trial at high or unclear risk of bias (Ishaque et al., 2012; PMID 22643043) and noting no independent replication (Hung et al., 2011; PMID 21036578). The best-use line's anti-aging effects via AMPK, measured in no human trial, and the 200 to 600 mg/day range, which the trials do not support, are removed. Mixed evidence stays C. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionSAM-e: the Sarris dose corrected, Peng relabeled as no difference from active drugs either, the 2026 add-on null and the 2025 network ranking added, osteoarthritis retyped as self-report, mania and serotonin signals added
Recordsam-e
What happenedText corrections after the letters were set in October. The dose line attributed 1,600 to 3,200 mg/day to Sarris 2020 (PMID 31712971), which used 800 mg/day in a 49-person pilot whose 3.76-point difference favoring SAM-e did not reach significance; both are now stated. Peng et al. (2024; PMID 38199136) found no difference from imipramine or escitalopram as well as from placebo. Added: a third null add-on trial (Alkema et al., Epigenomics, 2026; PMID 42027147), the 2025 network meta-analysis ranking the add-on effective by indirect comparison (Cheng et al., PMID 40314175) with the note that direct trials govern, and the Soeken osteoarthritis pool (2002; PMID 12019049). The endpoint types are corrected: clinician-rated scales in depression, self-reported pain in osteoarthritis. Safety now records the mania or hypomania reports and the serotonin-syndrome-like case. Letters unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionSelenium: the headline ref rewritten to the thyroid use it names, SELECT and the Cochrane review placed on the replete-adult row, the null clinical outcomes in thyroiditis added, the combination trial relabeled, forms and safety stated
Recordselenium
What happenedThe headline ref argued its letter from cancer and cardiovascular trials while the title named thyroid antibodies, cited a selenium plus coenzyme Q10 trial (Alehagen et al., Int J Cardiol, 2013; PMID 22626835) as selenium evidence, and called the Nutritional Prevention of Cancer trial suggestive when its skin cancer primary was null (Clark et al., JAMA, 1996; PMID 8971064). The ref now follows the graded use. The replete-adult row rested on one secondary analysis; SELECT (Lippman et al., JAMA, 2009; PMID 19066370), the form-matched 35,533-man trial, the Cochrane review (Vinceti et al., 2018; PMID 29376219) and Sel/Cel (Thompson et al., 2016; PMID 27530657) are its evidence now, with the badge restated as no benefit and the diabetes excess stated as a signal. The thyroid row adds the null clinical outcomes: quality of life unchanged in CATALYST (Larsen et al., 2024; PMID 38215286) and TSH, ultrasound and quality of life unchanged in untreated patients (Winther et al., 2017; PMID 27683225). The form note says the antibody effect is pooled across three selenium forms. Letters unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionSodium reduction protocol: the threshold framing corrected to reductions of a given size, the 133-trial dose-response pool and the hard-outcome Cochrane review added, the hypertensive subgroup effect stated
Recordsodium-reduction-under-2300-mg
What happenedThe name and description implied a benefit at a 2,300 mg threshold; the pooled trials (He et al., BMJ, 2013; PMID 23558162) tested an average 75 mmol/day reduction regardless of end level, with a larger fall in hypertensive than normotensive people, and DASH-Sodium (Sacks et al., N Engl J Med, 2001; PMID 11136953) shows the fall continuing below 2,300 mg. Added: the 133-trial dose-response meta-analysis (Huang et al., BMJ, 2020; PMID 32094151) and the Cochrane review of cardiovascular events (Adler et al., 2014; PMID 25519688), which is imprecise and explains why the letter stops at B. Potassium-enriched salt substitutes are named as a different intervention. B unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionSpermidine: the dose and form fields corrected to what the trials used, the pharmacokinetic and safety trials added, maker relationships stated
Recordspermidine
What happenedThe dose field read 1 to 2 mg/day from wheat germ extract as if a trial had supported it, and form_note said the supporting study used that preparation; the cited support was a mouse study (Eisenberg et al., Nat Med, 2016; PMID 27841876) and a dietary cohort (Kiechl et al., Am J Clin Nutr, 2018; PMID 29955838), and the one 12-month randomized trial, SmartAge (Schwarz et al., 2022; PMID 35616942), used 0.9 mg/day and was null. Both fields now say so. Added: Senekowitsch et al. (2023; PMID 37111071), 15 mg/day did not raise plasma spermidine; Keohane et al. (2024; PMID 39405978), 40 mg/day safe with minimal polyamine change, authors employed or funded by the product's maker; Pekar et al. (2021; PMID 33211152), an intake comparison without a described placebo arm; Alsaleh et al. (2026; PMID 42169618), immune markers after vaccination, part-funded by the wheat germ product's maker. evidence_type now records the randomized trials. D unchanged on both uses. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionSulforaphane: best use re-anchored to the one clinical question its trials address, the missed prediabetes primary endpoint and the null mechanism and hypertension trials added, the triple-reported Tehran trial counted once
Recordsulforaphane
What happenedbest_use led with NRF2 activation and claimed neuroprotective, cancer-preventive and cardiometabolic effects that no cited randomized trial measured; the record's own NRF2 trial (Wise et al., 2016; PMID 27832073) was null and a hemodialysis crossover (Ribeiro et al., 2024; PMID 37619675) found no change in NRF2 mRNA, with one small positive in non-dialysis kidney disease (PMID 38772511). The field now states glucose control in type 2 diabetes, the only clinical question the trials address. Added: Dwibedi et al. (2025; PMID 39929977), the Lund group's prediabetes trial that missed its prespecified primary endpoint with patent and stock interests disclosed; Christiansen et al. (2010; PMID 20805984), no effect on endothelial function or blood pressure in hypertension. Axelsson 2017 (PMID 28615356) is now described as a subgroup result, and PMIDs 22537070, 21559038 and 22325157 as one 81-patient Tehran trial reported three times. The dose field now names what was studied rather than a 10 to 40 mg label. C unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionTaurine: the exercise row's Route 2 sentence corrected, the aging absence check re-run against the perioperative mortality trial and the older-women trials, doses as studied
Recordtaurine
What happenedThe acute exercise row said a trial having been run is why the use is Route 2, under a Grade C; the sentence now says the trial found a benefit, which is why the use is C. The aging absence check claimed zero human randomized trials; the re-run query returns 13, and the note now names Van Stijn et al. (2015; PMID 26035756), a week-long perioperative course around hip fracture surgery that reported one-year mortality, null, and Abud et al. (2022; PMID 35700594) and Chupel et al. (2021; PMID 33586039), marker and fitness trials in older women, and explains why none tests the aging claim. Marcangeli et al. (2025; PMID 41061678) added as the observational counterpoint to the taurine-decline premise. Waldron et al. (2018; PMID 29546641) and Deng et al. (2025; PMID 40852891) added as context for the exercise row. The dose field now states 1 g single dose and 2.4 to 3 g/day as studied. All letters unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionPlasma exchange: the second trial restated as a different procedure with an unfavorable result, allocation by entry date carried into the ref, the company relationship stated
Recordtherapeutic-plasma-exchange
What happenedgrade_basis counted Borsky et al. (2025; PMID 40592961) as a second positive randomized trial of plasma exchange; it tested plasma removal without replacement, randomized only between 8 and 4 sessions with no untreated control, and reported GrimAge, the Hannum clock and the Dunedin pace of aging increasing. The ref now states that finding and that it does not replicate plasma exchange. Fuentealba et al. (2025; PMID 40424097) is now described as single-blinded with allocation by entry date in the ref's first sentence, and the record discloses that one author co-founded a company that sells plasma exchange, with no specific funding declared. C unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionTherapeutic ultrasound: the network meta-analysis restated as favorable to ultrasound, the two sham-controlled trials null on pain added, the low back pain Cochrane review added for scope
Recordtherapeutic-ultrasound
What happenedThe record described its only citation (Lin et al., 2026; PMID 42332459) as showing weak, sham-equivalent evidence; that network meta-analysis finds significant pain reduction with ultrasound and ranks it first for pain, mostly through indirect and active-comparator comparisons. The sham-equivalent wording is supported instead by Hussain et al. (2018; PMID 29767650) and Szajkowski et al. (2024; PMID 37721730), both null on pain against sham, now cited. Ansari et al. (2024; PMID 35315745) added for the mixed modality picture, and the Cochrane review of chronic low back pain (Ebadi et al., 2020; PMID 32623724) added so the page says the letter does not extend to pain elsewhere. C unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionTMG: the dose field tied to the 1.5 to 6 g/day that lowered homocysteine, the combination trial relabeled with its manufacturer relationship, the lipid-raising signal and the null trials added
Recordtmg
What happenedThe dose field read 500 to 1,000 mg/day; the trials that lowered homocysteine used 1.5 to 6 g/day, and Alfthan et al. (2004; PMID 15522136) found 1 g/day did not lower it significantly, which the field now states. Lu et al. (2023; PMID 36717385) was presented as a second betaine trial; it tested folic acid, B6 and B12 plus 1 g betaine, so it is relabeled as a combination that cannot grade betaine, with the study products made by a supplement manufacturer that employs one author. Added: Steenge et al. (2003; PMID 12730412) as independent replication; Alfthan 2004; the McRae 2013 (PMID 23997720), Ashtary-Larky 2022 (PMID 33764214) and Zawieja 2021 (PMID 31809615) pools, the latter two documenting higher total and LDL cholesterol at 4 g/day or more; Schwab et al. (2011; PMID 20978525), homocysteine unchanged at 4 g/day for 6 months; Olthof et al. (2006; PMID 16871332), no improvement in flow-mediated dilation despite lower homocysteine. The form_note claim that forms are equally effective, which no trial tested, is removed, and the track field no longer says betaine may lower LDL. B unchanged, now scoped to the studied dose. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionTongkat ali: the population named, a use row authored with as-studied form and dose, the maker-funded trial and the 2022 meta-analysis added, brand names removed
Recordtongkat-ali
What happenedThe record rested on Leitao et al. (2021; PMID 33541567) described as affecting testosterone-related measures; that trial's primary outcome was erectile function and its largest gains were in the extract-plus-training arm, so it does not isolate the extract. The use is now named as total testosterone in men with low testosterone, following Leisegang et al. (2022; PMID 36013514), whose pooled rise is significant in that group and not in healthy men. Added: Chinnappan et al. (2021; PMID 34262417), the largest placebo-controlled trial, funded and co-authored by the extract's maker, stated beside the letter; Chan et al. (2021; PMID 33559971); Morgado et al. (2024; PMID 37697053); Kotirum et al. (2015; PMID 26365449). A dose field now states the standardized water extracts at 100 to 600 mg/day, and the track field no longer names product brands. C unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectiontDCS: the chronic-pain network meta-analysis relabeled, the depression trial base authored as clinic and home-use rows, the large null trials and safety signals added
Recordtdcs
What happenedThe record's only citation (Li et al., 2026; PMID 42435147) is a network meta-analysis restricted to chronic musculoskeletal pain and does not test tDCS for depression, yet the endpoint was depression scales with no supporting trial. The record now carries the trial base: the individual patient data meta-analysis (Razza et al., 2026; PMID 41498282), SELECT-TDCS (Brunoni et al., JAMA Psychiatry, 2013; PMID 23389323) and ELECT-TDCS (Brunoni et al., N Engl J Med, 2017; PMID 28657871) as positives, DepressionDC (Burkhardt et al., Lancet, 2023; PMID 37414064), the international trial (Loo et al., Brain Stimul, 2018; PMID 29111077) and unsupervised home use (Borrione et al., JAMA Psychiatry, 2024; PMID 38170541) as large nulls, Woodham et al. (2025; PMID 39433921) as the maker-funded home-based positive, and Ren et al. (2025; PMID 40531534) finding tDCS alone not significant. Two use rows authored, clinic-administered and home-based, both C. endpoint_type corrected to clinician-rated; the not-replicated flag removed, the problem being inconsistency. Safety signals from the trials added to the page. C unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
CorrectionTMS for depression: the deep TMS trials scoped and their maker relationships stated, the suicidal ideation wording corrected, the 2026 pooled analyses and their risk-of-bias findings added
Recordtranscranial-magnetic-stimulation
What happenedgrade_basis scoped the A to left prefrontal high-frequency or theta-burst stimulation while two supporting trials used H1-coil deep TMS at 18 Hz (Levkovitz et al., 2015; PMID 25655160; Kaster et al., 2018; PMID 29946106), one in late-life depression; the ref, grade_basis and replication block now say so, and disclose the coil maker's sponsorship of the Levkovitz trial and in-kind equipment for the Kaster trial beside the Neuronetics funding already stated for O'Reardon. The record said a pooled analysis found no effect on suicidal ideation; Mehta et al. (2022; PMID 35044731) found a non-significant reduction in randomized trials, now stated. Added: Eren et al. (2026; PMID 41997374), 30 sham-controlled comparisons with larger effects in single-blind trials; Zhang et al. (2026; PMID 42383744), 141 trials with only 3 at low risk of bias; Orbo et al. (JAMA Netw Open, 2026; PMID 42418203), an independent sham-controlled theta-burst trial positive on blinded MADRS at day 10 and not sustained. The O'Reardon baseline-adjustment caveat is confirmed by that trial's abstract and stands. A unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
What happenedThe B rested on Goyal 2014 (PMID 24395196), which graded anxiety, depression and pain and found insufficient evidence on sleep, while the record described sleep. The letter now rests on the sleep evidence: Rusch 2019 (PMID 30575050), 18 trials, moderate strength against attention-matched controls, with supporting meta-analyses and trials. Three statements were removed for lack of support: that the effect adds to cognitive behavioral therapy for insomnia (de Entrambasaguas 2023, PMID 37271575, could not show it), that it works best for middle-of-the-night waking, and that benefit needs 20 or more minutes a day. The named app was removed. Letter unchanged at B. Editor adjudication, October 2026.
CorrectionRed and near-infrared light: graded use by use
Recordred-light-near-infrared-630-850nm
What happenedThe general page stated that the evidence for knee osteoarthritis pain and wound healing was small and mixed without citing it. It now carries four uses with their own letters and citations: skin aging C, on small trials including Lee et al. (J Photochem Photobiol B, 2007; PMID 17566756); knee osteoarthritis pain C, where meta-analyses disagree, Stausholm et al. (BMJ Open, 2019; PMID 31662383) positive and others not, mostly on lasers outside 630 to 850 nm; diabetic foot ulcer healing C, on three positive meta-analyses of small trials including Li et al. (Diabetes Res Clin Pract, 2018; PMID 30009935); venous leg ulcer healing C, on small trials with mixed results including Lundeberg and Malm (Ann Plast Surg, 1991; PMID 1793238). Headline letter unchanged at C. Editor adjudication, October 2026.
Correction40 Hz gamma: 'not replicated' flag removed, second meta-analysis explained
Recordgamma-40hz
What happenedThe record carried a 'not replicated' flag while describing 11 controlled trials; the flag is removed and the checklist corrected (several small trials, null clinical endpoints, one positive imaging endpoint). Wu 2025 (PMID 40855942), a meta-analysis reporting large cognitive gains, is now cited with the reason it is not relied on: it pools transcranial brain stimulation with sensory stimulation. Letter unchanged.
Correction5-HTP: fatigue claim corrected to a null, grade re-scoped to depressive symptoms, safety signals added
Record5-htp
What happenedThe record presented Truyens 2022 (PMID 35940251) as support for a C on fatigue; that trial was null on its primary endpoint and every secondary one, so fatigue in inactive inflammatory bowel disease is now a D Route 2 use. The depression evidence the record alluded to is now cited: the Cochrane review Shaw 2002 (PMID 11869656), the pooled analysis Javelle 2020 (PMID 31504850), and the small trials Jangid 2013 (PMID 23380314) and Meloni 2020 (PMID 32067288), with their quality warnings. Safety: the unresolved eosinophilia-myalgia syndrome association and 19.6 percent adverse events after a single dose in Jackson 2026 (PMID 42160304). Headline C held, scoped to depressive symptoms, pending editor confirmation.
CorrectionALCAR: dose line, best use and citations corrected; two null and harm follow-up trials added
Recordalcar
What happenedThe dose line said 500 to 1,500 mg/day, below every dose that reported benefit (2 to 3 g/day) and within the range the Cochrane review Rolim 2019 (PMID 31201734) found ineffective; corrected. The best-use line claimed 'cognitive aging' and 'aging-related neuropathy', neither of which any trial tested; it now names mild cognitive impairment, mild Alzheimer's disease and diabetic neuropathy, and drops the mechanism. Thal 2000 (PMID 10994000), the second large null Alzheimer's trial, and Hershman 2018 (PMID 29361042), showing the chemotherapy neuropathy harm persisting at two years, are added. Li 2015 (PMID 25751285) is now described as a pooled analysis of neuropathic pain, not cognition, and Pennisi 2020 (PMID 32408706) as a narrative review. Letter unchanged.
What happenedThe description said protein supports lean mass 'particularly in older adults'. The evidence runs the other way: Morton 2018 (PMID 28698222) found the effect shrinks with age, Bhasin 2018 (PMID 29532075) was null at almost this record's dose in older men, and Obasi 2025 (PMID 41385355) found no benefit in healthy older people. Tagawa 2022 (PMID 36057893) shows the strength benefit depends on concurrent resistance training, now stated. Nunes 2022 (PMID 35187864) added with its industry ties, and the dairy-industry support behind Morton 2018 stated. Wu 2016 (PMID 26797090) relabeled as a narrative review. Endpoint type set to surrogate (lean mass), which is what the grade rests on. Letter unchanged.
CorrectionAkkermansia: the 'confirming' trial was null between groups, the scale-up trial missed its primary endpoint, maker ties stated
Recordakkermansia
What happenedThe record called Zhang 2025 (PMID 39879980) an RCT confirming metabolic benefit; it reports no significant between-group difference, with benefit only in a low-baseline subgroup. The largest trial, Suenaert 2026 (PMID 42343233, 142 adults), was null on its primary insulin-sensitivity endpoint and was run by the company that makes the product; it is now cited. Perraudeau 2020 (PMID 32675291) tested a five-strain combination and cannot grade Akkermansia alone; its authors are all employees of its maker. The co-founder and patent ties of the Depommier 2019 (PMID 31263284) senior authors are stated. Two trials the search found are added: Mount 2026 (PMID 42120725), company-run, 90 adults, less weight regain after dieting on pasteurized MucT, a different endpoint from the graded use; and Kang 2024 (PMID 39683431), a different strain tested on leg strength. Strains and forms are no longer pooled as one. Headline C held pending editor confirmation.
CorrectionAlpha-GPC: healthy-aging and athletic claims replaced with what the trials tested; four trials and a TSH signal added
Recordalpha-gpc
What happenedThe best-use line implied a healthy-aging result that no trial has produced, and an athletic power claim no cited paper supported; both are rewritten to the diagnosed populations and doses the trials used. The dose line said 300 to 600 mg/day; the Alzheimer's and diabetes trials used 1,200 mg/day. Added: Jeon 2024 (PMID 39300341), Sohn 2025 (PMID 39703111), Marcus 2017 (PMID 29042830) with its finding that TSH fell at 500 mg/day, and Kerksick 2024 (PMID 39683633), null on performance. Sagaro 2023 (PMID 36683513) is described as a meta-analysis mostly of alpha-GPC added to donepezil. Letter unchanged.
CorrectionApigenin: wrong attribution corrected, the one human trial described as the combination it tested
Recordapigenin
What happenedThe record credited Kellenberger 2011 (PMID 21641214) with showing apigenin inhibits CD38; that paper names other flavonoids and not apigenin. Escande 2013 (PMID 23172919) is the apigenin paper and is now cited for it. Henderson 2024 (PMID 38302501), listed as a 'systems approach', is a randomized crossover trial of a branded multi-ingredient product with the maker's founder and an employee among the authors; it is now described that way and the record says 'standalone apigenin' where it says no trial exists. Letter unchanged.
CorrectionArterosil: the case series described in full, maker ties stated
Recordarterosil
What happenedThe record called Burke and Jennings 2023 (PMID 38404609) an uncontrolled case series but not that its six patients were also on drugs, other supplements and lifestyle changes, nor that the first author sits on the maker's scientific advisory board; both are now stated. Shimada 2021 (PMID 34226572), the only randomized trial, now carries its authors' ties to a rhamnan sulfate producer, and the form note no longer says MonitumRS is the only studied extract. Letter unchanged.
CorrectionAshwagandha: sleep claim now cited, two extracts told apart, a null pooled analysis and a liver-injury series added
Recordashwagandha
What happenedThe best-use line claimed sleep quality with no sleep trial cited; Cheah 2021 (PMID 34559859) and Langade 2021 (PMID 32818573) now carry it. The ref treated two different extracts as one and overstated Lopresti 2019 (PMID 31517876): HAM-A and cortisol fell, the DASS-21 did not reach significance, testosterone did not differ from placebo; corrected. The strength signal is no longer called single-trial: Ziegenfuss 2018 (PMID 30463324) is added with its maker funding, and Lee 2026 (PMID 42738987) rates the pooled effect fragile. Albalawi 2025 (PMID 40746175), null on perceived stress, and Arumugam 2024 (PMID 39348746), positive, sit side by side. Björnsson 2020 (PMID 31991029), cholestatic liver injury cases, is added. Letter unchanged.
What happenedThe record cited only the ASPREE mortality report, McNeil 2018 (PMID 30221595), and attributed the disability-free survival and bleeding results to it. Those come from the companion papers by the same group, now cited: McNeil 2018 (PMID 30221596), the primary endpoint report, and McNeil 2018 (PMID 30221597), the cardiovascular and bleeding report. The mortality finding is stated as the paper states it: higher all-cause death, mostly cancer, called unexpected by the authors, and not confirmed over the decade of follow-up in Wolfe 2025 (PMID 40796244) and Shah 2025 (PMID 41043446), which found no long-term benefit, a higher event rate after stopping, and persisting bleeding. ASCEND, Bowman 2018 (PMID 30146931), and ARRIVE, Gaziano 2018 (PMID 30158069), are now cited and described as the different populations they are. Letter unchanged.
CorrectionAvoiding ultra-processed food: the B now rests on randomized replication, not an observational review
Recordavoiding-ultra-processed-food
What happenedThe record said the Hall trial was 'confirmed by' Lane 2024 (PMID 38418082), an umbrella review of observational studies that cannot confirm a trial or carry a grade. The randomized replications are now cited: Hamano 2024 (PMID 39267249) and Dicken 2025 (PMID 40760353). Sciarrillo 2024 (PMID 39163976) answers the no-washout objection. The nulls and limits are shown: Rego 2026 (PMID 41255123) and Aramburu 2024 (PMID 38988861). The description now says what the B covers, short-term intake and weight over 1 to 8 weeks. The replication search owed since October is closed. Letter unchanged.
CorrectionBacopa 600 mg+: the dose and extract the trials used stated; acute dose finding, a null trial's side effects and GI signal added
Recordbacopa-monnieri-600-mg-55-bacosides
What happenedThe description claimed broad cognitive improvement at 600 mg plus from pooled trials that used 300 to 450 mg/day and improved two measures, and said the lack of a hard endpoint is why the letter is not A, which is not the site's rule. Rewritten to what Kongkeaw 2014 (PMID 24252493), Pase 2012 (PMID 22747190) and Tiemtad 2026 (PMID 41678913) show. Added Downey 2013 (PMID 23281132): acutely, 320 mg improved performance and 640 mg did not. Morgan 2010 (PMID 20590480) added for its result and its gastrointestinal side effects, also seen in Lopresti 2025 (PMID 41091332). The not-replicated flag stands for the 600 mg plus dose. Letter unchanged; the name is on the editor's list.
CorrectionBeetroot: the nulls and the independent replication cited, the short-term pooled analysis labeled as such, exercise claim removed
Recordbeetroot
What happenedThe best-use line claimed vascular and exercise support that no cited trial measured; exercise is now stated as not graded. Siervo 2013 (PMID 23596162) pooled trials of 2 hours to 15 days and is described as acute evidence. The null trials the record left out are cited: Sundqvist 2020 (PMID 32091599), Bondonno 2015 (PMID 26135348), Fejes 2024 (PMID 38546454), and the record now says the effect is smaller or absent in people already on antihypertensive treatment. Kerley 2018 (PMID 29553033), an independent positive replication on 24-hour pressure, is added. Letter unchanged.
CorrectionBerberine 500 mg protocol: within-arm changes no longer presented as placebo differences; replication, dose and interaction evidence cited
Recordberberine-500-mg-3-day-with-meals
What happenedThe description gave Zhang 2008 (PMID 18397984) within-arm changes as differences versus placebo, called the single 36-person Yin 2008 pilot (PMID 18442638) a metformin equivalence, and said Zhang's primary outcome was HbA1c when it was plasma glucose and lipids; all corrected. Xie 2022 (PMID 36467075) is described as pooling berberine with and without other drugs. The placebo-controlled replication is now cited: PREMOTE (PMID 33024120), Ming 2021 (PMID 34365978), Zhao 2023 (PMID 37598753). The 'mandatory interaction check' wording is replaced by the interaction evidence itself, Guo 2012 (PMID 21870106). The record now says the B is drawn from 1.0 to 1.2 g/day trials and that 1.5 g/day matches only the pilot. Letter unchanged.
CorrectionBerberine HCl: mechanisms removed from the use line, replication and lipid evidence cited, interaction and absorption claims sourced
Recordberberine
What happenedThe best-use line listed AMPK activation and microbiome modulation, which are mechanisms, and insulin sensitivity, which Zhang 2008 (PMID 18397984) did not show by clamp; rewritten to the surrogates the trials measured. Added PREMOTE (PMID 33024120), the placebo-only pooled analyses Zhao 2023 (PMID 37598753) and Blais 2023 (PMID 36941490) for lipids, and Lei 2026 (PMID 41543854), null on visceral and liver fat. The dihydroberberine absorption claim now cites its source, Moon 2021 (PMID 35010998), with its supplier funding and null glucose result. The CYP interaction evidence, Guo 2012 (PMID 21870106), is on the record. The unsourced 'higher doses in Chinese medicine' line is gone. Letter unchanged.
CorrectionBeta-carotene: CARET described as the combination it tested, the two large null trials and three pooled analyses added, the mortality harm stated
Recordbeta-carotene
What happenedThe record attributed the CARET harm to 'supplemental beta-carotene' without saying the trial gave beta-carotene with retinyl palmitate, cited the post-intervention follow-up, Goodman 2004 (PMID 15572756), as the primary result and said the excess 'persisted' when it continued as a nonsignificant trend; the primary result, Omenn 1996 (PMID 8602180), is now cited and the follow-up described exactly. The record also said no trial had enrolled anyone who stopped smoking long ago; the Physicians' Health Study, Hennekens 1996 (PMID 8602179), 39 percent former smokers, and the Women's Health Study, Lee 1999 (PMID 10601381), were null and are now cited. The mortality harms in ATBC and CARET, and the pooled lung, stomach and cardiovascular findings of Druesne-Pecollo 2010 (PMID 19876916), Zhang 2023 (PMID 36715090) and O'Connor 2022 (PMID 35727272), are stated. The closing inference that harm is a property of the supplement rather than the dose is withdrawn. Letter unchanged.
CorrectionBitter melon: the one cited trial described as the null-to-equivocal result it was, four pooled analyses added, no form or dose claimed
Recordbitter-melon
What happenedThe ref said Kim 2020 (PMID 32951763) 'modestly affected glycemic measures'; HbA1c did not change and the fasting glucose fall is within-group only. The pooled analyses that show the inconsistency are now cited: Peter 2019 (PMID 30385422) and Zhang 2024 (PMID 38784554) positive, Laczko-Zold 2023 (PMID 38274207) and the Cochrane review Ooi 2012 (PMID 22895968) null, with the Cochrane finding that no preparation was tested twice. Mes 2025 (PMID 40199408) added for prediabetes. The record now says no single form or dose carries the letter. Letter unchanged.
CorrectionBoron: the null controlled trials stated as nulls, the hormone claim traced to its source, review's industry tie stated
Recordboron
What happenedThe best-use line implied the question was untested; the small controlled trials exist and were null, now stated: Ferrando 1993 (PMID 8508192) and its second report Green 1994 (PMID 7889885), Meacham 1994 (PMID 7889886), and Beattie 1993 (PMID 8329361), added. The steroid-hormone claim is traced to Nielsen 1987 (PMID 3678698), a non-randomized study of 12 women, cited as context. Rondanelli 2020 (PMID 32540741) is described as a narrative review whose conclusion rests on non-randomized studies, with two authors at a commercial ingredient company's research unit. Letter unchanged.
CorrectionBovine colostrum: the meta-analysis stated in full, the trial where permeability rose added, immune evidence cited separately, dose and population stated
Recordcolostrum
What happenedThe ref said the meta-analysis Hajihashemi 2024 (PMID 38361147) found colostrum 'affected' permeability and 'some immune measures'; it found a fall in one ratio with 99 percent heterogeneity, no effect on I-FABP, and reports no immune measures. Buckley 2009 (PMID 22253980), where permeability rose on colostrum during running training, was missing and is cited. Morrison 2014 (PMID 25068884), null in the heat, added. Immune evidence now has its own citation, Główka 2020 (PMID 32276466), mostly null, and the self-reported respiratory-symptom pooled analysis Jones 2016 (PMID 27462401) is shown as context. The record now says the trials mixed athletes and patients and used doses from 0.5 g/day to 1.7 g/kg/day. Letter unchanged.
CorrectionBPC-157: 'no trial run' corrected to 'no result published'; the third injection route and the clinic attribution stated exactly
Recordbpc-157
What happenedThe record said no human randomized trial 'has been run'; the developer group's review, Sikiric 2012 (PMID 22300085), states a phase II trial in inflammatory bowel disease was run, with no result indexed, so the record now says no result has been published. The dose line omitted the route used in the interstitial cystitis pilot, Lee 2024 (PMID 39325560): injection around the bladder lesion at cystoscopy, 10 mg; added. 'One clinic' is restated as what the abstracts support: one lead author, one named clinic and two unnamed private-clinic reports. Letter unchanged.
CorrectionC60: the third animal lifespan study added, the rat result labeled unreproduced, grammar fixed
Recordc60
What happenedThe record said the animal data 'disagree with itself'; now the animal studies disagree with each other, and the third one is cited: Shytikov 2021 (PMID 33849306), in which C60-in-oil mice outlived oil-fed but not water-fed controls, pointing at the olive oil. Baati 2012 (PMID 22498298) is labeled small and not reproduced. Letter unchanged.
CorrectionCa-AKG: the customer report described exactly, the product's twice-daily schedule removed from the dose line, endpoint type corrected
Recordca-akg
What happenedThe best-use line called the Demidenko 2021 report (PMID 34847066) an analysis of 'self-reported users'; it measured DNA methylation age in 42 customers, retrospectively, without controls, on a multi-ingredient product, and was authored in part from the company that sells it. All of that is now stated. The dose line presented a commercial product's twice-daily schedule as if trial-derived; removed, leaving the 1 g dose the ABLE trial (Lim 2025, PMID 40819772) tests. The endpoint type is now surrogate, since the planned human readout is a methylation clock. Letter unchanged.
CorrectionCaloric restriction: 'pre-specified' corrected to post hoc, the clocks that did not move and the bone loss stated, achieved dose given
Recordcaloric-restriction
What happenedThe record called Waziry 2023 (PMID 37118425) a pre-specified analysis; the paper says post hoc, and it also reports that PhenoAge, GrimAge and other clocks did not change, now stated. Telomere length, Hastings 2024 (PMID 38504468), no net change, added. The trial randomized 218, not 220, and achieved about 12 percent restriction against the 25 percent target, now stated. The safety signal was missing: bone density fell at spine and hip (Romashkan 2016, PMID 26992237; Villareal 2016, PMID 26332798). Cardiometabolic improvement is now sourced to Kraus 2019 (PMID 31303390), and Racette 2017 (PMID 29045325) shows absolute fitness and strength fell. The DunedinPACEAn epigenetic test that estimates how fast a person is aging now, in years of biological aging per calendar year. inventors' commercial license is disclosed. Letter unchanged.
CorrectionCholine: the graded claim scoped to what was tested (maternal dose comparison, infant endpoint), the null trial and the funding stated
Recordcholine
What happenedThe record was named 'Choline' with a generic use line while its only evidence was Caudill 2018 (PMID 29217669): 26 mothers, 930 versus 480 mg/day, no placebo, infant reaction time. The population, dose, comparator and n are now stated, with the egg and beef industry part-funding the paper discloses. The larger placebo-controlled trial, Cheatham 2012 (PMID 23134891), was null and is cited, with the 7-year follow-up Bahnfleth 2022 (PMID 34962672) and the Gould 2025 (PMID 40077755) review that finds the evidence insufficient. Adult use is stated as ungraded, with Deuster 2002 (PMID 12502178) null. Letter unchanged.
CorrectionCiticoline: dose line corrected to what the trials used, the Cochrane conflict and attention null stated, IDEALE moved off the evidence list
Recordciticoline
What happenedThe dose line said most trials used 250 to 500 mg; the trials cited used 1,000 mg/day (Cohen 2003, PMID 12865605; the IDEALE study, Cotroneo 2013, PMID 23403474), 1,000 then 2,000 mg/day (Spiers 1996, PMID 8624220) or 500 mg/day, and the Cochrane review, Fioravanti and Yanagi 2005 (PMID 15846601), reports heterogeneous doses and routes; corrected. The Cochrane review's declared conflict, that its principal reviewer was an investigator in some included trials, and its finding of no benefit on attention are now stated. IDEALE, an open study with a non-randomized control group, is linked as context rather than listed as evidence, and the 'observational' flag that described it is gone. Added: Bonvicini 2023 (PMID 36678257), a positive meta-analysis whose authors rate the studies poor, and Spiers 1996 (PMID 8624220), where the memory benefit appeared only in a subgroup picked after analysis. Letter unchanged.
CorrectionCold-water immersion: the endpoint line corrected to what the pooled analysis found, the one large trial cited, the blunted-strength-gain signal made a safety note with its two meta-analyses
Recordcold-water-immersion
What happenedThe endpoint line listed inflammation and mood; Cain 2025 (PMID 39879231) found inflammation markers rose for an hour after immersion and mood did not change, so the headline endpoint now reads stress at 12 hours, sleep quality and quality of life, and mood and inflammation are each a D Route 2 use. 'Few small RCTs' is corrected: one trial, Buijze 2016 (PMID 27631616), carries 3,018 of the 3,177 pooled participants and is now cited and graded as a C use on self-reported sickness absence. Roberts 2015 (PMID 26174323) showed smaller strength and muscle gains, not only blunted signaling; Grgic 2023 (PMID 35068365) and Malta 2021 (PMID 33146851) replicate it, and the three now sit together as a harm signal for immersion after lifting. 'Signalling' is now spelled signaling. Headline letter unchanged; whether the headline should be split further is for the editor.
CorrectionCollagen: vitamin C removed from the dose line, the gelatin study and the qualitative review relabeled, a third joint-pain trial, a second skin meta-analysis and the bone trial added
Recordcollagen
What happenedThe dose line said trials dosed collagen alongside vitamin C; only Shaw 2017 (PMID 27852613) did, and that was an 8-man, 3-day study of vitamin C-enriched gelatin measuring a synthesis marker, now labeled mechanistic context. Clark 2008 (PMID 18416885) used 10 g and Zdzieblik 2017 (PMID 28177710) 5 g without vitamin C; corrected. Choi 2019 (PMID 30681787) is a qualitative review, not a meta-analysis, and is relabeled; the meta-analysis flag now rests on Myung and Park 2025 (PMID 40324552), null in independent and high-quality skin trials, and Pu 2023 (PMID 37432180), positive with biases noted and no difference by collagen source, which also removes the unsupported marine-versus-bovine preference. Kviatkovsky 2023 (PMID 37551682), a 9-month trial with an NIH training grant, is added on joint pain. König 2018 (PMID 29337906), a 12-month bone-density trial, is noted and not graded. Letter unchanged; the joint-pain split is on the decision sheet.
CorrectionConcurrent training sequence: the three syntheses described as overlapping rather than independent, the 2026 umbrella review and a null trial added, author names and the corrigendum stated
What happenedThe record called three meta-analyses independent replications; Murlasits, Kneffel and Thalib 2018 (PMID 28783467), Eddens, van Someren and Howatson 2018 (PMID 28917030) and Gao and Yu 2023 (PMID 36776981) pool largely the same small trials, and the text now says so, with the third author of each of the first two named and Gao 2023's corrigendum (PMID 37215175) attached. Held 2026 (PMID 41762427), an umbrella review of 17 meta-analyses finding no significant sequence effect, and Wilhelm 2014 (PMID 25449853), a null comparison in older men, are added as the counterweight. Letter unchanged: B on consistent small pooled effects, not A.
CorrectionCreatine for cognition: two citations relabeled, the meta-analysis authors' creatine-industry ties and a published double-counting critique stated, the null trials at 5 g/day and the 20 g/day dose of the positive trial added
Recordcreatine-3-5-g-day
What happenedThe record cited Candow 2015 (PMID 25993883) for creatine plus training on cognition; that trial measured lean mass and strength only and is now labeled as such. Avgerinos 2018 (PMID 29704637) is a systematic review of six trials without pooling, not a trial, and is relabeled. Prokopidis 2023 (PMID 35984306) now carries its own declaration, an author on the advisory board of a creatine manufacturer and another who advised a creatine seller, and the letter by Eckert and Pascher 2023 (PMID 36644917) alleging double counting, with the authors' reply (PMID 36644912). Added at the record's own dose: Sandkühler 2023 (PMID 37968687), the largest preregistered trial, null on both primary tests with side effects more frequent on creatine (RR 4.25), now a safety note; Alves 2013 (PMID 24098469), 24 weeks in older women, null. Rawson 2008 (PMID 18579168) is null in young adults. McMorris 2007 (PMID 17828627), the older-adult positive trial, used 20 g/day for one week, so the description no longer implies the older-adult effect was shown at 3 to 5 g. Xu 2024 (PMID 39070254) is added as the later meta-analysis, pooling patients with healthy adults. Letter unchanged.
CorrectionDASH: the DASH-Sodium design described correctly, the trial population and hypertensive subgroup stated, independent replication and the 2025 Cochrane hard-outcome review cited
Recorddash-dietary-pattern
What happenedThe record described DASH-Sodium as a crossover of three sodium levels within the DASH pattern; Sacks 2001 (PMID 11136953) randomized participants in parallel to a control diet or DASH and crossed sodium levels within each, and the control arm is now stated. Appel 1997 (PMID 9099655) enrolled adults with systolic pressure under 160 and diastolic 80 to 95, with a larger effect in the hypertensive subgroup; both now appear. The B's replication requirement is now met on the page by Saneei 2014 (PMID 25149893) and Filippou 2020 (PMID 32330233), meta-analyses by other groups, with Juraschek 2026 (PMID 41206973) on durability in a community setting. The 'no trial reported events' statement now cites Bensaaud 2025 (PMID 40326569), the Cochrane review that found almost no events across five small trials. Letter unchanged.
CorrectionDIM: the trial's changed primary endpoint, completer count and capsule supplier stated, the 'best use' no longer presented as a benefit, the largest DIM trial and two smaller ratio trials added
Recorddim
What happenedThomson 2017 (PMID 28560655) now carries what its full text reports: the primary endpoint was originally breast density and was changed to the urinary 2/16 ratio on the monitoring board's advice after recruitment problems, the original primary was null, 98 of 130 randomized women completed, and the active and placebo capsules were supplied by the maker of the studied product while the NCI funded the work. The best-use line called the ratio change a benefit; no trial has linked it to a cancer outcome, and the line now says so. Castañon 2012 (PMID 22075942), the largest DIM trial, null on cervical cytology and HPV, Dalessandri 2004 (PMID 15623462) and Godínez-Martínez 2023 (PMID 36111381), where 75 mg/day did not raise the ratio, are added. The formulation's maker is no longer named on the record. The tamoxifen-metabolite signal stays in the avoid and drug-conflict fields the page renders. Letter unchanged.
CorrectionEEG neurofeedback: the independent placebo-neurofeedback trial cited, the network meta-analysis described as what it is, the graded population stated once
Recordeeg-neurofeedback
What happenedThe October adjudication had already moved this record to D Route 2 on the blinded and sham-controlled evidence. Remaining from the review: van Dongen-Boomsma 2013 (PMID 24021501), the independent double-blind placebo-neurofeedback trial in 41 children, was named in the search record but not cited; it is now on the page with its null result and its chance-level guess rates. Mei 2026 (PMID 42358407) is now described as a network meta-analysis of 37 randomized trials of digital interventions whose neurofeedback ranking rests on unblinded ratings, not as a systematic review. The evidence note names the graded population, children and adolescents, and says that nothing on the page implies benefit for adults or consumer headsets. The sham-controlled trial (PMID 32853703; follow-up PMID 36521694) and the two meta-analyses, Cortese 2016 (PMID 27238063) and Westwood 2025 (PMID 39661381), stand. Letter unchanged.
CorrectionEGCG: anti-inflammatory and antioxidant claims removed, the glucose claim tied to its one pooled source, the maker-run beverage trial relabeled, the 12-month extract trial added with its liver-enzyme and triglyceride findings and two nulls
Recordegcg
What happenedThe best-use line claimed anti-inflammatory and antioxidant benefit and fasting glucose with no cited outcome; the first two are removed and glucose now rests on Zheng 2013 (PMID 23426037), a 1.48 mg/dL pooled drop with no HbA1c change. Nagao 2005 (PMID 15640470) was run by researchers at the company that makes the catechin beverage it tested, measured body fat in 35 men and did not measure LDL cholesterol or test an extract; relabeled as context. Hartley 2013 (PMID 23780706) now says what it found: no trial reported cardiovascular events and the green tea results were unstable on sensitivity analysis. Xu 2020 (PMID 32434539), already cited, is now described. Peng 2014 (PMID 25176280) is now stated to show its blood pressure effect only in low-dose subgroups. Added: Samavat 2016 (PMID 27806972), the largest extract trial at the record's dose, LDL down about 4 percent and triglycerides up; Dostal 2015 (PMID 26051348), its safety report with ALT elevations in 6.7 percent against 0.7 percent, now in the avoid field; Kim 2011 (PMID 22027055) and Momose 2016 (PMID 27324590) as independent confirmations of the LDL effect; Igho-Osagie 2020 (PMID 33188386), null on lipids and blood pressure in short trials. Letter unchanged.
CorrectionErgothioneine: the dose line tied to the trials, the human uptake study added, the cognitive endpoint typed as measured, whole-mushroom trials scoped out
Recordergothioneine
What happenedThe October adjudication had already corrected the 'no human randomized trial' statement for Yau 2024 (PMID 39544014). Remaining from the review: the dose line said 5 to 30 mg/day with no trial behind it; it now states the one efficacy trial's 25 mg three times a week and the uptake study's 5 or 25 mg/day. Cheah 2017 (PMID 27488221), the first human administration of pure ergothioneine, is added with its mostly non-significant biomarker trends, which is why no antioxidant claim is made. The endpoint type moves from surrogate to functional because the one trial's outcome is a measured cognitive test. The form note says whole-mushroom trials do not support purified ergothioneine. The three observational papers, Cheah 2016 (PMID 27444382), Wu 2022 (PMID 36139790) and Wu 2021 (PMID 34673145), are labeled association only. Letter unchanged, still under review.
CorrectionExosome therapy: skin endpoint typed once as surrogate, three further split-face trials added with the maker-funded replication disclosed, the pooled analysis of uncontrolled studies removed from the hair, knee and systemic rows
Recordexosome-therapy
What happenedThe headline said functional, the skin row said self-report and its note said surrogate; instrument readings are surrogate, and all three now say so. 'One randomized split-face trial' is corrected: Choi 2026 (PMID 42403177) repeated Park 2023 (PMID 37377400) with the same product, funded and supplied by its maker, ExoCoBio, from the same group, so it is not independent replication, and Yen 2026 (PMID 42635327) and Park and Park 2026 (PMID 41752855) are independent but unblinded trials of different products. Huang 2026 (PMID 41800727) is described as n=6 in the ref as well as the note. Stack 2026 (PMID 41800726), which pooled mostly uncontrolled studies and contains no knee or systemic trial, no longer sits under the hair, knee or systemic rows. The hair row's search note now says Amini 2025 (PMID 40141845) lacks the publication-type tag the query relied on, and the knee row's Bolandnazar 2024 (PMID 39465400) is described in full. Letters unchanged; the hair hold is on the decision sheet.
CorrectionFasting-mimicking diet: 'pilot-scale' corrected, the Wei 2017 finding scoped to its randomized comparison, two null trials against active comparators and the 11-trial meta-analysis added, type 2 diabetes graded as its own use
Recordfasting-mimicking-diet
What happenedThe description called the human evidence pilot-scale; Wei 2017 (PMID 28202779) randomized 100 adults, Micarelli 2025 (PMID 39970875) 102 in crossover, van den Burg 2024 (PMID 38546821) 100 for 12 months, and Mohammadzadeh 2025 (PMID 40287774) pooled 11 trials; corrected. Wei 2017's randomized comparison showed weight, fat, blood pressure and IGF-1 only, with the glucose, lipid and CRP results post hoc in at-risk participants; the ref now says so. Espinoza (PMID 41372565) is dated 2026 as PubMed does, with 30 people, 8 days and differences not significant at all time points. Added: Mishra 2023 (PMID 40604264), no difference from a Mediterranean diet, and Sadeghian 2021 (PMID 33420673), no weight difference from continuous energy restriction, as the nulls; Brandhorst 2024 (PMID 38378685) as the inventor group's biological-age analysis. The type 2 diabetes trial (PMID 38546821), co-funded by the maker, is a separate C use rather than support for healthy adults. The kit's product name is no longer on the record. Headline letter unchanged; B versus C is on the decision sheet.
CorrectionFisetin: the unvalidated maintenance dose removed, the liposomal claim replaced with the one bioavailability trial, the human trials in other uses listed
Recordfisetin
What happenedThe October adjudication had already scoped the 'no human trial' statement to the senolytic use. Remaining from the review: the dose line gave a 100 to 200 mg/day anti-aging maintenance dose that no trial in healthy or aging adults supports; it is removed, and the doses actually used, 100 mg/day in colorectal cancer (Farsad-Naeimi 2018, PMID 29541713) and 200 mg/day in obese men (Alipour 2026, PMID 42218768 and PMID 41683255), are stated as other uses. The form note claimed liposomal fisetin improves absorption with no citation; the one human bioavailability trial, Krishnakumar 2022 (PMID 36304817), tested a hydrogel formulation, and the note now says so. Yousefzadeh 2018 (PMID 30279143) is labeled mouse data only. Letter unchanged.
CorrectionFolic acid: the stroke use relabeled to the population and dose actually tested, the adenoma null shown as replicated and pooled, the long-term serrated-lesion signal and the no-cancer-increase meta-analysis added
Recordfolic-acid-supplemental
What happenedThe stroke use was labeled 'folate-deficient'; CSPPT (Huo 2015, PMID 25771069) enrolled hypertensive adults without prior stroke or MI, not people selected for deficiency, gave 0.8 mg/day with enalapril in both arms, and Zhang 2024 (PMID 38824900) found efficacy did not vary by baseline folate, so the label now names the population, the dose and the fortification condition. Yang 2024 (PMID 39155933), the primary-prevention meta-analysis that is null overall and positive only without fortification, now sits beside the positive one. The headline's 'not-replicated' flag is removed: Wu 2009 (PMID 19864409) and Logan 2008, ukCAP (PMID 18022173), replicated the null of Cole 2007 (PMID 17551129) and Figueiredo 2011 (PMID 21170989) pooled all three at RR 0.98. Added: Passarelli 2019 (PMID 31401653), more sessile serrated lesions with extended use, as a safety note; Vollset 2013 (PMID 23352552), no overall cancer increase across 49,621 people; Gao 2013 (PMID 23682073), the open trial on initial occurrence, a different question. The maker's support for CSPPT reported in secondary sources is not asserted, because the JAMA full text was not read. Letters unchanged.
CorrectionFucoidan: the lipid claim removed, the null trial and the adverse-direction trial added, the vaccine-response trial cited, extracts stated as non-interchangeable
Recordfucoidan
What happenedThe record said Liu 2025 (PMID 39645105) showed lipid and glucose effects; its abstract reports a smaller rise in glycated serum protein and lower inflammatory markers with no lipid result, and the ref now says so. Added: Wright 2019 (PMID 30312135), a maker-funded placebo-controlled trial null on insulin resistance, lipids, HbA1c and glucose at 1 g/day for 90 days; Hernández-Corona 2014 (PMID 24611906), where HOMA insulin resistance rose on fucoidan; Negishi 2013 (PMID 24005608), the influenza-vaccine antibody trial that carries the immune half of the best-use line. The record now states that fucoidan products differ by seaweed source and molecular weight, so trials of different extracts do not replicate each other. Letter unchanged.
CorrectionGABA: the trial described as what it measured, its population stated, the systematic review and the one polysomnography trial added
Recordgaba
What happenedThe ref said Guimarães 2024 (PMID 38321713) affected stress measures; its abstract reports sleep quality, negative affect, depression scores and heart-rate variability, with no stress result, in 30 overweight women who were also starting an exercise program, and the record now says so. Added: Hepsomali 2020 (PMID 33041752), the systematic review of 14 placebo-controlled trials that rates the stress evidence limited and the sleep evidence very limited; Byun 2018 (PMID 29856155), the one trial with polysomnography, reporting within-group change only. Letter unchanged.
CorrectionGeneral health checks: the record name no longer claims serial multi-biomarker screening was tested, the largest modern trial and the 2026 review added, dashes replaced
What happenedThe record was named for serial multi-biomarker screening while its own scope note said the Cochrane trials tested health checks of their era; the name now says multi-organ screening of asymptomatic adults. Added: Jørgensen 2014 (PMID 24912589), Inter99, 59,616 people, null on ischemic heart disease, stroke and mortality at 10 years; Wang 2026 (PMID 42414985), a systematic review of 22 randomized trials through 2025 confirming no mortality or cardiovascular benefit; both beside Krogsbøll 2019 (PMID 30699470). The confidence intervals now read 'to' rather than a dash. Letter unchanged.
CorrectionGeranylgeraniol: the unverified 'ongoing trial' claim withdrawn, the mouse genetic model labeled as such, two human trials on other endpoints added as context with their seller ties
Recordgg
What happenedThe record said the primary human trial of the statin-muscle claim is ongoing; no registered trial was located in this pass, and the claim is withdrawn rather than left unsourced. Osaki 2026 (PMID 42323079) is now described as a mouse genetic model, not as establishing the human mechanism. Added as context, scoped away from the statin claim: D'Adamo 2026 (PMID 42807157), 150 healthy adults, GG alone null on plasma CoQ10 and questionnaires, first author on the advisory board of a company that sells GG; Jurgelewicz 2026 (PMID 42222203), a fixed-order placebo-then-GG study null on testosterone overall, one author employed by the sponsor. The 'no human trial' language is now scoped to the statin-muscle claim. Letter unchanged.
CorrectionGlutathione: 'one small trial' corrected to mixed trials, two null placebo-controlled trials added, the liposomal pilot labeled as seller-funded and uncontrolled, the first trial's funding stated as unconfirmed
Recordglutathione
What happenedThe record rested on Richie 2015 (PMID 24791752) alone and called the grade 'one small RCT'; Allen and Bradley 2011 (PMID 21875351), NIH-funded, found no change in glutathione status or oxidative stress markers at 1,000 mg/day, and Søndergård 2021 (PMID 33740389) found no change in oxidative stress markers, so the grade reason is now mixed small trials and the best-use line no longer lists oxidative stress markers as a supported use. Sinha 2018 (PMID 28853742) is cited for form only: a 12-person uncontrolled pilot of liposomal glutathione funded by a company that sells it. Richie 2015's funder is not in its indexed record and an ingredient maker lists the trial as its own, so the record does not call it independent. Letter unchanged.
CorrectionGlyNAC: the 'independent' trial restated as maker-run and maker-funded, the dose and duration gap stated, the 'elevated demand' population no longer presented as tested, one randomized trial not several
Recordglynac
What happenedThe healthy-older-adults use called Lizzo 2022 (PMID 35821844) an independent trial; its paper discloses that the sponsor holds and licenses patents on glycine plus N-acetylcysteine and markets the products, so it is a maker-funded null, which strengthens rather than weakens it, and its 2.4 to 7.2 g/day for 2 weeks is now set against the originating group's roughly 14 g/day for 16 weeks. The other use said 'randomized trials' in the plural; only Kumar 2023 (PMID 35975308) is randomized and placebo-controlled, the 2021 study (PMID 33783984) is an open-label pilot, and the note now says so. The 'populations with elevated demand' label described a post hoc subgroup from the sponsor trial rather than how Kumar 2023 enrolled people, so the use and title now name older adults. The unverifiable 'BMI above 27' entry criterion is removed. The 'sponsored' flag is replaced by a funding_basis block naming who sponsored which trial. Letters unchanged; the D versus C question on the healthy older adults use is on the decision sheet.
CorrectionGymnema: the cited trial restated as null on glycemic outcomes, the trial and meta-analysis that carry the glycemic claim added, the populations named, a liver-injury case added as a safety note
Recordgymnema
What happenedThe ref said Zuñiga 2017 (PMID 28459647) affected glycemic measures; it did not change the metabolic syndrome components, insulin secretion or insulin sensitivity, and was positive only for weight, BMI and VLDL, so it is now labeled null on glycemic outcomes. The positive glycemic data come from Gaytán Martínez 2021 (PMID 32460589), 2-hour glucose and HbA1c lower in 30 adults with impaired glucose tolerance, and Zamani 2023 (PMID 36580574), a six-trial meta-analysis its authors rate low quality; both are added and the best-use line now rests on them. The record now names the populations studied, none of them healthy adults. Shiyovich 2010 (PMID 20856101), toxic hepatitis attributed to Gymnema, is added to the avoid field. Letter unchanged.
CorrectionHesperidin: the 'CRP null' wording updated to the three later meta-analyses, the VCAM-1 effect traced to its exploratory subgroup, form and dose stated, a null vascular trial added
Recordhesperidin
What happenedThe record said CRP was null; that was true of Lorzadeh 2019 (PMID 30991044), but Huang 2024 (PMID 39279783), Ouyang 2026 (PMID 41883255) and Zhu 2026 (PMID 42434414) each pool a modest CRP reduction, so the inflammatory evidence is restated. The VCAM-1 effect came from Salden 2016 (PMID 27797708), where it was a trend overall and significant only in an unadjusted exploratory subgroup; the record now says so, and that the pool mixes hesperidin 2S and purified hesperidin at different doses in different populations. Gilcher 2026 (PMID 42605853), null on flow-mediated dilation at a dietary dose, is added. Letter unchanged.
CorrectionHMB: the cancer-patient review no longer carries claims about older or trained adults, its maker ties disclosed, the population-specific meta-analyses and null trials added, dose and form stated
Recordhmb
What happenedThe only citation, Prado 2022 (PMID 35301826), is a vote-counting review of patients with active cancer in which 73 percent of studies gave HMB combined with amino acids, with authors employed by or paid by a maker of HMB-containing oral nutritional supplements; the ref attributed to it findings in older and trained adults it never studied. It is relabeled. The record now rests on the population-specific evidence: Li 2025 (PMID 40248035), small gains in adults over 50; Wang 2026 (PMID 41934514), no added benefit with resistance training; Osuka 2021 (PMID 34081113), null primary in older women with low muscle mass; Gu 2025 (PMID 39999663), small gains in diagnosed sarcopenia; Tritto 2019 (PMID 30859862), null in trained men. Rathmacher 2020 (PMID 32857128) is context as a manufacturer-authored combination trial. Dose and form are stated. Letter unchanged; a split by population is on the decision sheet.
CorrectionCombined HRT for primary prevention: the coronary finding corrected to its final adjudication, the firm harms named, the unchanged mortality stated, the follow-up reports and two reviews added
What happenedThe grade basis listed excess coronary heart disease as a finding; the 2002 interim hazard ratioHow often an event happened in the treated group compared with the control group over the same period. A ratio of 0.80 means 20 percent fewer events. was only nominally significant and the final adjudicated result, Manson 2013 (PMID 24084921), was 1.18 (95% CI 0.95 to 1.45), which the 2026 Cochrane review, Bofill Rodriguez (PMID 42695385), rates as probably little to no difference. The firm harms, invasive breast cancer, stroke, venous thromboembolism, dementia in women 65 and over and gallbladder disease, are now what the record names. Manson 2017 (PMID 28898378) is added so the record says all-cause mortality was not changed during the trial or over 18 years, which the earlier text could be read as implying. Gartlehner 2022 (PMID 36318128), the USPSTF review, is added. Rossouw 2002 (PMID 12117397) is relabeled as the interim report. Whether the manufacturer supplied study drug is not asserted, because the full text was not read. Letter unchanged.
CorrectionOral hyaluronic acid: the knee trial restated as a trend with an age-subgroup signal, the null knee trial added, the review relabeled, three skin trials and a meta-analysis added, structural claims removed, every maker tie disclosed
Recordoral-hyaluronic-acid
What happenedThe ref said Tashiro 2012 (PMID 23226979) improved knee osteoarthritis symptoms; both groups improved, hyaluronic acid showed a trend overall and significance only in those aged 70 or under, and the record now says so. Kalman 2008 (PMID 18208600), null on its primary pain endpoint, is added. Kawada 2014 (PMID 25014997) is a review and is relabeled as background. The best-use line claimed joint lubrication and cartilage health and gut-barrier support; no trial measured cartilage or lubrication and no human trial tested the gut, so both are removed. Added on skin: Hsu 2021 (PMID 34203487), Dolečková 2025 (PMID 41422283), the largest trial, and Amin 2025 (PMID 40911749), the 7-trial meta-analysis; on knees, Sugiyama 2024 (PMID 38234616), self-rated improvement without objective change. The dose line now states each trial's dose and that one often-cited joint trial used a multi-ingredient preparation. Every trial's manufacturer tie is in the funding block. Letter unchanged; splitting skin from joints is on the decision sheet.
CorrectionIntermittent fasting: the record now says why C rather than B, the one-year trials with their LDL and dropout signal added, the 2025 network meta-analysis and 2026 Cochrane review added, the fatty-liver trial relabeled
Recordintermittent-fasting
What happenedThe ref said 'Grade C on consistent RCT evidence limited to cardiometabolic surrogates', which under the site's rule describes a B. The letter is C because against daily calorie restriction the fasting pattern adds nothing, and the record now says so with the trials: Trepanowski 2017 (PMID 28459931), one year, weight loss equal to daily restriction, LDL 11.5 mg/dL higher and 38 percent dropout in the fasting arm; Schübel 2018 (PMID 30475957), HELENA, 50 weeks, equivalent not superior; Semnani-Azad 2025 (PMID 40533200), 99 trials, an edge only in short trials; Garegnani 2026 (PMID 41692034), Cochrane, little to no difference from regular dietary advice. Cioffi 2018 (PMID 30583725) is stated as pooling 8 to 24 week trials only. Kord Varkaneh 2022 (PMID 35958257) is relabeled as a small open trial in fatty liver disease against usual diet, with its null lipid and glycemic results. Letter unchanged.
CorrectionKetogenic diet: drug-resistant epilepsy in children graded as its own use (B, self-report cap), the LDL rise quantified from two meta-analyses, the infant trial and the matched-energy weight analysis added
Recordketogenic-diet
What happenedThe record carried one C across every use while its own umbrella review, Patikorn 2023 (PMID 37231411), rated seizure reduction as high-quality evidence. Drug-resistant epilepsy in children and adolescents is now its own use: Neal 2008 (PMID 18456557) and Lambrechts 2017 (PMID 27027847), two independent positive randomized trials, and Martin-McGill 2020 (PMID 32588435), the Cochrane pool; seizure diaries are unblinded self-report, so B. Schoeler 2023 (PMID 37977712), KIWE, is added so the use excludes infants and the comparison with a further drug. The LDL harm now cites Wang 2024 (PMID 39097343) and Chang 2026 (PMID 41621647), and Żurawski 2026 (PMID 42588148) states the matched-energy weight difference. The description names the epilepsy population. Headline letter unchanged; whether the epilepsy use should be A is on the decision sheet.
CorrectionL-citrulline: the blood-flow study relabeled, the null blood pressure and performance meta-analyses added, L-citrulline and citrulline malate told apart, the diastolic claim scoped to 6 g/day or more
Recordcitrulline
What happenedThe ref said Gonzales 2017 (PMID 28940638) showed exercise-performance effects; it measured femoral blood flow during calf exercise in 25 older adults, with a benefit only in men that lost significance after adjustment, and is relabeled as a vascular surrogate study. Mirenayat 2018 (PMID 30284051), null on brachial and aortic blood pressure, is added beside Barkhidarian 2019 (PMID 30788274), whose diastolic effect appeared only at 6 g/day or more and whose systolic interval was borderline. Viribay 2022 (PMID 36079738) and Harnden 2023 (PMID 37155582), null on aerobic and endurance performance, are added; Trexler 2019 (PMID 30895562) and Wang 2026 (PMID 42356270) show the small strength effects rest largely on citrulline malate, now stated as a different form. Letter unchanged; a split into blood pressure and performance rows is on the decision sheet.
What happenedThe question put to the editor was whether the C should rest on independent trials only or on all of them with the investigator affiliation stated. Decided: as built. Schneider et al. (Circ Cardiovasc Qual Outcomes, 2012; PMID 23149426) and Norris et al. (Front Med (Lausanne), 2025; PMID 40177279) both count, the Maharishi affiliation of the investigators is stated in the record, and the Cochrane extraction (Rees et al., 2024; PMID 38358047) showing no clear difference stands beside the positive trial. Letter unchanged. Decided October 2026 by editor adjudication (Arnold Sandlow, D.C.).
CorrectionVitamin D3 plus K2 protocol: retail-dose name kept, untested-at-these-doses statement leads the record
Recordvitamin-d3-2-000-4-000-iu-k2-mk-7-100-mcg
What happenedThe protocol is named for the common retail pairing, which no trial has tested; the nearest combination trial, AVADEC (Diederichsen et al., Circulation, 2022; PMID 35465686), used MK-7 720 mcg with D3 1,000 IU and was null on its primary endpoint. Decided: keep the name readers search for and open the record with the statement that these doses are untested, rather than rename to doses no reader buys. The citation_incomplete review is closed on that basis; the letter stays C. Decided October 2026 by editor adjudication (Arnold Sandlow, D.C.).
CorrectionL-theanine protocol renamed to the dose the trials used
Recordl-theanine-200-mg-30-60-min-before-sleep
What happenedThe protocol was named for 200 mg taken 30 to 60 minutes before sleep. Hidese et al. (Nutrients, 2019; PMID 31623400) gave 200 mg a day for four weeks with no stated time, and the Bulman et al. meta-analysis (Sleep Med Rev, 2025; PMID 40056718) pools trials of varied timing, mostly inside combination products. No trial tested the bedtime timing in the name, so the name now states the dose studied, L-Theanine 200 mg/day. Letter unchanged at C. Decided October 2026 by editor adjudication (Arnold Sandlow, D.C.).
CorrectionAlpha-lipoic acid protocol renamed to the racemic form and doses the trials used
Recordalpha-lipoic-acid-r-ala-300-600-mg-fasted
What happenedThe protocol was named R-ALA 300 to 600 mg fasted. Every cited trial gave racemic alpha-lipoic acid with no fasting instruction: Ansar et al. (Saudi Med J, 2011; PMID 21666939), 300 mg a day; Ziegler et al. (Diabetes Care, 2006; PMID 17065669, SYDNEY 2), 600 to 1,800 mg a day; Ziegler et al. (Diabetes Care, 2011; PMID 21775755, NATHAN 1), 600 mg a day for four years; and Han et al. (Eur J Endocrinol, 2012; PMID 22837391) pooled intravenous trials. The name now reads Alpha-Lipoic Acid (racemic) 300 to 600 mg/day, and the tracking note no longer asserts an R-form equivalence no trial measured. Letter unchanged at C; the review opened October is closed. Decided October 2026 by editor adjudication (Arnold Sandlow, D.C.).
CorrectionPhosphatidylserine: headline C stated for the bovine-cortex form, soy form added as its own use at D Route 2
Recordphosphatidylserine
What happenedThe C rested on Cenacchi et al. (Aging (Milano), 1993; PMID 8323999), a trial of bovine-cortex phosphatidylserine, a preparation no longer sold, while the soy-derived form on the shelf had two null trials and a protocol at D Route 2. The search for this decision found a second positive bovine trial, Crook et al. (Neurology, 1991; PMID 2027477; 149 adults), so the bovine evidence is replicated; it stays C because the written B attaches to a form that can be obtained. Decided: the record follows the evidence for each form. The headline C is stated for the bovine-cortex preparation and says it is not sold; the soy-derived form is its own use at D Route 2 on Jorissen et al. (Nutr Neurosci, 2001; PMID 11842880) and Kato-Kataoka et al. (J Clin Biochem Nutr, 2010; PMID 21103034). The review opened October is closed. Decided October 2026 by editor adjudication (Arnold Sandlow, D.C.).
CorrectionSerrapeptase: the 'no human randomized trial' line was false; the record is now graded by use
Recordserrapeptase
What happenedThe record's title said Grade D, no human randomized trial, while its own citation was a randomized trial of swelling after dental surgery. Five randomized placebo-controlled trials exist: four found less postoperative swelling (Tachibana 1984, Al-Khateeb 2008, Tamimi 2021, Kee 1989) and one found no effect (Chopra 2009), and a 2013 systematic review rates them small and poorly designed. The record now grades two uses. Swelling after oral or sinus surgery is C: small, mixed, short-term trials. Systemic, cardiovascular and longevity use stays D on Route 1, because no trial has tested it, which is the use the enzyme is sold for. The headline letter stays D.
CorrectionDIM: the cited trial found it lowered the active tamoxifen metabolites, and the record did not say so
Recorddim
What happenedThe DIM record cited Thomson 2017 for a favorable change in an estrogen-metabolism biomarker. The same trial, in 130 women taking tamoxifen for breast cancer, found plasma endoxifen, 4-hydroxytamoxifen and N-desmethyltamoxifen lower on DIM than on placebo (P<0.001), and breast density unchanged. Endoxifen is tamoxifen's main active form. Whether the drop reduces tamoxifen's benefit has not been tested. The record now states the finding in its caution, its drug-conflict text and a new interaction entry. The grade is unchanged; the omission was the defect.
CorrectionCitation corrections on nine records after an independent check of 45 papers
Recordsite-wide
What happenedA second check of 143 machine-judged grades, and five independent reviews of that check, were reconciled against PubMed's own records in October 2026. Nine records keep their letter and gain corrected text. Benfotiamine cited only its two null trials; the two positive short trials (Haupt et al., Int J Clin Pharmacol Ther 2005, BEDIP; Stracke et al., Exp Clin Endocrinol Diabetes 2008, BENDIP) and the null 24-month trial (Fraser et al., Diabetes Care 2012) are now on the record. Glucosamine called the GAIT dose the sulfate dose when GAIT used the hydrochloride; the two positive (Reginster et al., Lancet 2001; Pavelka et al., Arch Intern Med 2002) and two null (Hughes and Carr, Rheumatology 2002; Fransen et al., Ann Rheum Dis 2015) sulfate trials are now cited by salt and endpoint. Chromium gains the two further meta-analyses that disagree with the one it cited (Asbaghi et al., Pharmacol Res 2020; Yin and Phung, Nutr J 2015). PQQ claimed two cognition trials and cited two papers that measured none; the three trials that did are now cited (Itoh et al., Adv Exp Med Biol 2016; Shiojima et al., J Am Nutr Assoc 2022; Tamakoshi et al., Food Funct 2023). Phosphatidylserine states that its positive trial used the bovine form and that the soy form has a null trial (Jorissen et al., Nutr Neurosci 2001). Berberine credited the wrong paper with the metformin comparison. Alpha-lipoic acid gains the null 4-year NATHAN 1 trial (Ziegler et al., Diabetes Care 2011) and its adverse event rate. Vitamin E's prostate cancer increase in SELECT (Klein et al., JAMA 2011) is significant, not a trend, and ATBC's hemorrhagic stroke deaths are now stated. Methylene blue's one trial is described as what it was, a single dose after fear-extinction sessions. Eighteen further records carry an internal Grade under review status with the reason, and no letter moves on them until the missing trials are searched.
CorrectionLion's mane protocol renamed to the dose the trial used
Recordlion-s-mane-1-000-mg-fruiting-body
What happenedThe protocol was named "Lion's Mane 1,000 mg (fruiting body)" while its only trial, Mori et al. (Phytother Res, 2009; PMID 18844328), gave four 250 mg tablets of fruiting-body powder three times daily, about 3 g/day, for 16 weeks. A dose in a name is read as the dose that was tested, and 1,000 mg is a consumer dose no trial has tested on cognition. The protocol is renamed at the studied dose with an as-studied block; the letter (C) and the record identifier are unchanged. Found by the dose-in-name check that became gate_g183 the same day.
CorrectionRoute and wording corrections on eleven records after a use-specific search
Recordsite-wide
What happenedA use-specific PubMed search in October 2026 found randomized trials on records that said none existed, and found null trials that move three records from Route 1 (untested) to Route 2 (tested, no benefit). No letter changes. Boron: small randomized trials exist and were null (Ferrando et al., Int J Sport Nutr 1993; PMID 8508192; Meacham et al., Environ Health Perspect 1994; PMID 7889886); the route moves from 1 to 2 and the letter stays D. Exosome therapy: a triple-blind placebo-controlled knee trial was null (Bolandnazar et al., BMC Musculoskelet Disord 2024; PMID 39465400), so the knee use moves from Route 1 to Route 2; a 20-man randomized hair pilot of a plant-derived formulation (Amini et al., Life 2025; PMID 40141845) is now named and the hair letter is held at D under review. Reducing anticholinergic burden: randomized deprescribing trials have been run and found no clinical benefit (Taylor-Rowan et al., Cochrane Database Syst Rev 2023; PMID 38063254; Braithwaite et al., Age Ageing 2023; PMID 37740900); the route moves from 1 to 2, the false line is removed, and 'prudent practice' wording is withdrawn. Alcohol reduction: the record now names the randomized abstinence trial in atrial fibrillation (Voskoboinik et al., N Engl J Med 2020; PMID 31893513) as a different use, keeps Route 1 for mortality and major events, and drops the word 'prudent'. Arterosil: 'no human randomized trial' was false as written; a small randomized trial for constipation exists (Shimada et al., Sci Rep 2021; PMID 34226572), so the line is scoped to vascular outcomes. C60: 'no human trial has been run' was false as written; topical fullerene trials exist (Liu et al., J Clin Oncol 2026; PMID 41861269), so the line is scoped to oral C60. Ca-AKG: 'no human randomized trial' was false as written; a bone-marker trial at 6 g (Filip et al., Int J Vitam Nutr Res 2007; PMID 17896582) exists and the ABLE trial has enrolled (Lim et al., Exp Gerontol 2025; PMID 40819772); the line is scoped to aging outcomes. Fisetin: 'no human randomized trial has reported results' was false as written; small trials in other uses exist (Hodgin et al., Int J Environ Res Public Health 2021; PMID 33802381), so the line is scoped to the senolytic use. NAD+ (direct): one randomized pharmacokinetic study of an oral NAD+ formulation now exists (Kornilov et al., Geroscience 2026; PMID 42530810), so the line is scoped to clinical outcomes. Spermidine: 'no human randomized trial has been run' was false as written; SmartAge (Schwarz et al., JAMA Netw Open 2022; PMID 35616942) was a 12-month randomized memory trial and was null; the line is scoped to lifespan and mortality. Ergothioneine: 'no human randomized trial' was false; a 19-person randomized pilot in mild cognitive impairment exists (Yau et al., J Alzheimers Dis 2024; PMID 39544014). The letter is held at D under review, not raised, until it is replicated. PectaSol: 'no randomized trial for any use' was false; two placebo-controlled trials in other uses were null (Lau et al., JACC Basic Transl Sci 2021; PMID 33532663; Andrews et al., Contemp Clin Trials Commun 2020; PMID 31872160). The prostate use has no randomized trial, so it stays on Route 1; the manufacturer's role is disclosed. Aged garlic extract: renamed to the doses its trials used, 480 mg/day for blood pressure (Ried et al., Eur J Clin Nutr 2013; PMID 23169470) and 2.4 g/day in the plaque trials; the name previously read 1.2 to 2.4 g/day, a range no trial tested. The letter (B) is unchanged.
CorrectionSpermidine: absence query scoped to the aging claim; memory graded as its own use at D Route 2
Recordspermidine
What happenedThe stored absence query for spermidine was unscoped and had been returning the cognition trials since July while the record claimed zero; gate_g169 was reporting the mismatch as unreproducible. The aging claim keeps D on Route 1 with a query scoped to mortality, lifespan and longevity (zero randomized trials). Memory in older adults with subjective cognitive decline is now its own use at D on Route 2: the 12-month SmartAge trial of Schwarz et al. (JAMA Netw Open, 2022; PMID 35616942; 100 adults) found no difference from placebo on its primary memory outcome, and the 3-month pilot of Wirth et al. (Cortex, 2018; PMID 30388439) reported only a within-group gain in 30 people. The aging claim's own citations are unchanged: Eisenberg et al. (Nat Med, 2016; PMID 27841876), lifespan in mice, and Kiechl et al. (Am J Clin Nutr, 2018; PMID 29955838), observational dietary intake. The headline letter is unchanged.
CorrectionUrolithin A: funding and investigator ties stated beside the evidence
Recordurolithin-a
What happenedFunding stated beside each trial. The company that makes the urolithin A product tested funded or ran five of the six randomized trials cited: Andreux 2019 (PMID 32694802), Liu 2022 (PMID 35050355), Singh 2022 (PMID 35584623), Whitfield 2025 (PMID 40839339) and Denk 2025 (PMID 41174221). Its employees, founder and board members are among the authors, and Liu 2022 (PMID 35050355) states the company had a role in design, conduct and analysis. The one independent trial, Zhao 2024 (PMID 39487653), was publicly funded in China. Whitfield 2025 (PMID 40839339), maker-funded and null on running performance in trained runners, is now cited. Letter unchanged.
CorrectionAshwagandha (standardized root extract): funding and investigator ties stated beside the evidence
Recordashwagandha
What happenedFunding stated beside the letter. All three trials behind the Grade B were run with the extract maker's money or product: the standardized root extract supplied by its maker in Chandrasekhar 2012 (PMID 23439798) and Wankhede 2015 (PMID 26609282), and Lopresti 2019 (PMID 31517876) funded by the maker of the extract it tested. Letter unchanged.
CorrectionCollagen Peptides: funding and investigator ties stated beside the evidence
Recordcollagen
What happenedFunding stated in the evidence. The knee-pain trial Zdzieblik 2017 (PMID 28177710) has a Collagen Research Institute author, and the skin meta-analysis Myung 2025 (PMID 40324552) found no effect in trials without industry funding, so the positive skin results come from company-funded trials. Letter unchanged.
CorrectionPterostilbene: funding and investigator ties stated beside the evidence
Recordpterostilbene
What happenedFunding corrected. Earlier today this record said PubMed recorded no funding for the one trial cited, Riche 2014 (PMID 25057276); that was true of the indexed entry, but the full text states a grant from the company that makes the pterostilbene tested, which also supplied the pterostilbene and placebo and reports having had no role in data collection or analysis. Now stated beside the letter.
CorrectionVascanox HP (Nitric Oxide / Noxa24): funding and investigator ties stated beside the evidence
Recordvascanox
What happenedTies stated beside the letter. The single open-label study, Houston 2023 (PMID 37849591), has an author on the staff of Calroy Health Sciences, which sells the product, and its authors hold a patent application covering the composition. The indexed record names no funder. Letter unchanged.
CorrectionPectaSol Modified Citrus Pectin (MCP): funding and investigator ties stated beside the evidence
Recordpectasol-mcp
What happenedFunding stated beside the letter. The prostate study Keizman 2021 (PMID 34959847) was sponsored by the maker of PectaSol, and its co-author Isaac Eliaz is the company's developer; he is also the sole author of the review Eliaz 2019 (PMID 31683865). The earlier study, Guess 2003 (PMID 14663471), names no funder. Letter unchanged.
CorrectionAlpha-GPC (L-Alpha-Glycerylphosphorylcholine): funding and investigator ties stated beside the evidence
Recordalpha-gpc
What happenedFunding stated in the evidence. The one randomized trial behind the letter, De Jesus Moreno Moreno 2003 (PMID 12637119), names no funder in its indexed record; the systematic review Sagaro 2023 (PMID 36683513) and the stroke cohort Lee 2021 (PMID 34817582) were publicly funded. The October review found that alpha-GPC trials which do state a funder were paid for by alpha-GPC makers. Letter unchanged.
CorrectionAcetyl-L-Carnitine (ALCAR): funding and investigator ties stated beside the evidence
Recordalcar
What happenedFunding stated in the evidence. The neuropathy meta-analysis Li 2015 (PMID 25751285) reports that most of the trials it pooled were funded by the manufacturer of the acetyl-L-carnitine tested, and names a potential commercial bias; the trial that found harm, Hershman 2013 (PMID 23733756), was funded by the National Cancer Institute and the Medical Research Council. Letter unchanged.
CorrectionHyaluronic Acid (Oral): funding and investigator ties stated beside the evidence
Recordoral-hyaluronic-acid
What happenedTies stated beside the letter. Every trial behind the Grade C was run with a manufacturer's product and a manufacturer's researchers among the authors: one manufacturer in Tashiro 2012 (PMID 23226979) and Kawada 2015 (PMID 25834304), a second in Gao 2023 (PMID 38009035). Kawada 2014 (PMID 25014997) is a review by the first manufacturer's employees, not a trial, and is now described as one. Letter unchanged.
CorrectionRhodiola Rosea: funding and investigator ties stated beside the evidence
Recordrhodiola
What happenedTies stated beside the letter. All four trials, Shevtsov 2003 (PMID 12725561), Darbinyan 2000 (PMID 11081987), Spasov 2000 (PMID 10839209) and Olsson 2009 (PMID 19016404), tested one proprietary standardized extract, and each has a scientist from the institute that developed and sells it among its authors; none names a funder. Letter unchanged.
CorrectionFolic Acid (supplemental, 1 mg/day): funding and investigator ties stated beside the evidence
Recordfolic-acid-supplemental
What happenedFunding checked for the stroke-prevention use. The October review reports nonfinancial support to the CSPPT trial, Huo 2015 (PMID 25771069), from Shenzhen AUSA Pharmed, maker of the combination pill. PubMed's record of the trial carries no conflict statement, so the use note states only what the indexed record shows; the full report is to be read before the review's statement is added.
CorrectionLactoferrin: funding and investigator ties stated beside the evidence
Recordlactoferrin
What happenedFunding stated beside the letter. The single adult trial, Oda 2023 (PMID 37764743), states that research funds and test foods were provided by the company that makes the lactoferrin tested, and five of its nine authors are its employees. Letter unchanged.
What happenedFunding stated in the evidence. The single pilot trial, Fitzgerald 2021 (PMID 33844651), was supported by an unrestricted grant from the company that makes the two supplements in the program, and its two lead authors use the program in practice, hold a related patent application and earn from its educational products. Letter unchanged.
CorrectionFasting-mimicking diet (FMD, 5-day cycles): funding and investigator ties stated beside the evidence
Recordfasting-mimicking-diet
What happenedFunding stated in the evidence. Wei 2017 (PMID 28202779) was publicly funded but used a diet provided by L-Nutra, which licenses it from USC, and two authors hold L-Nutra equity; Espinoza 2026 (PMID 41372565) was sponsored by L-Nutra, with two of its employees among the authors. Letter unchanged.
Correction40Hz Gamma Sensory Stimulation: funding and investigator ties stated beside the evidence
Recordgamma-40hz
What happenedFunding stated in the evidence. The largest sham-controlled trial, OVERTURE, Hajós 2024, and the MRI paper from the same trial, Da 2024 (PMID 38073386), are now cited; both were funded by Cognito Therapeutics, maker of the device, and written mostly by its employees. OVERTURE missed its primary clinical outcome. The meta-analysis the letter rests on, Ang 2025 (PMID 41381439), was publicly funded. Letter unchanged.
CorrectionMesenchymal stem cell therapy (intravenous, allogeneic): funding and investigator ties stated beside the evidence
Recordmsc-therapy
What happenedFunding stated in the evidence. Ruiz 2026 (PMID 41747733) was NIH-funded and its senior author is chief scientific officer and an equity holder of Longeveron, maker of the cells; Tompkins 2017 (PMID 28977399) was foundation-funded with Longeveron employees among the authors; the Chinese trial Zhu 2024 (PMID 38679727) was government-funded. Letter unchanged.
CorrectionMulti-cancer early detection blood test (cell-free DNA): funding and investigator ties stated beside the evidence
Recordmced-blood-test
What happenedFunding stated beside the letter. The NHS-Galleri trial, Sasieni 2026 (PMID 42776074) with the test-performance paper Neal 2026 (PMID 42773209), was funded by GRAIL, which sells the test, with GRAIL employees among the authors. The evidence already said so; it now also prints beside the letter.
CorrectionEnergy Lounger moved from PEMF to photobiomodulation
Recordphotobiomodulation-skin-msk
What happenedThe Energy Lounger was listed under pulsed electromagnetic field devices. It is a red and near-infrared light lounger, so it now sits under photobiomodulation. It carries no grade of its own. The modality grade rests on targeted low-level laser trials, and one randomized trial of whole-body light (Forsey et al., Lasers Med Sci 2023; PMID 37099210) found no effect on exercise performance.
CorrectionGlucosamine: a dose credited to a paper this record does not cite
Recordglucosamine
What happenedThe dose field credited its 1,500 mg/day figure to "the Zheng et al. mortality analysis". No Zheng paper is cited by this record and none was ever attached to it. The dose actually comes from Clegg et al. (PMID 16495392), the randomized trial the record does cite. The record's two cohort mortality citations are Li (PMID 32253185) and King (PMID 33219063), and both analyze regular glucosamine use without establishing any dose. The attribution was removed and the dose is now credited to the trial that used it. Nothing about the grade changed, because the grade never rested on the misattributed paper. This is the same class of defect as the two fabricated attributions found in the July audit: a named author standing where a citation should be, passing every check that reads identifiers because it contains none.
CorrectionMitoQ: a dose credited to a paper this record does not cite
Recordmitoq
What happenedThe dose field credited "Macpherson et al." alongside the trial it does cite. This record has never cited a Macpherson paper. Its vascular dose comes from Rossman et al. (PMID 29661838), which used 20 mg/day, and its other two citations are Broome (PMID 35623315) and Gane (PMID 20492507). The attribution was removed. Found in the same pass as the glucosamine attribution and for the same reason: a sweep for author names in dose and form fields that do not appear in the record's own citation list. A named author with no identifier beside it is invisible to every gate on this site that checks PMIDs, which is all of them.
CorrectionOmega-3: high-dose icosapent ethyl corrected from Grade A to Grade B, and the headline with it
Recordomega-3
What happenedThe record carried Grade A on the replicated hard-outcome route, and the reading published to readers said so in those words. It was not replicated. The two PMIDs on that use were REDUCE-IT (Bhatt et al., New England Journal of Medicine, 2019; PMID 30415628), positive, and STRENGTH (Nicholls et al., JAMA, 2020; PMID 33190147), null. One positive trial and one null does not meet the Grade A requirement that an effect replicate across independent research groups. JELIS (Yokoyama et al., Lancet, 2007; PMID 17398308) was assessed as the replication candidate and rejected as insufficient at this dose: 1,800 mg/day against the 4 g/day this record grades, open-label against a statin-only control, in a Japanese population not selected for elevated triglycerides. It is now cited on the record as supporting evidence rather than replication. Grade C was considered and rejected. C describes a single unrepeated trial, and two positive randomized trials in roughly 26,000 patients is not that. Grade B is the honest reading: supported by further trials, not standing alone, not replicated at the graded dose.
CorrectionOmega-3: the post-myocardial-infarction use corrected from Grade A to Grade B
Recordomega-3
What happenedThis record grades omega-3 by use. The use reading secondary prevention after myocardial infarction held Grade A on GISSI-Prevenzione Investigators, group-authored (Lancet, 1999; PMID 10465168), a single randomized trial of 11,324 patients reporting reduced all-cause mortality. The endpoint is hard and the trial is large, but the result has not replicated on modern background therapy. ASCEND (New England Journal of Medicine, 2018; PMID 30146932) randomized 15,480 adults to the same 1 g/day dose and found no reduction in serious vascular events. One large randomized trial on a hard clinical endpoint supports B; what is absent is a second trial of the same intervention in the current treatment era. Nothing about the 1999 result has changed. The high-dose icosapent ethyl use remains Grade A and the general-population primary prevention use remains Grade D, both unchanged. ASCEND is now recorded on this record explicitly rather than left out.
CorrectionRed yeast rice: corrected from Grade A to Grade B, because its two citations are one trial
Recordred-yeast-rice
What happenedThis record carried Grade A on two PMIDs. Both come from the China Coronary Secondary Prevention Study. Lu et al. (American Journal of Cardiology, 2008; PMID 18549841) is the trial itself, roughly 4,870 adults after myocardial infarction, and Li et al. (Journal of Clinical Pharmacology, 2009; PMID 19602720) is that same trial's elderly hypertensive subgroup. Two papers from one trial population are not independent replication, and Grade A requires replication of the same intervention in a separate trial. The letter is corrected to B, which is what one large randomized trial on hard clinical outcomes supports. Nothing about the trial's result has changed. The citation for the subgroup paper is corrected in the same edit: it was attributed to the Journal of Geriatric Cardiology and is in the Journal of Clinical Pharmacology.
CorrectionMagnesium, cardiovascular events and all-cause mortality: corrected from Grade C to Grade D
Recordmagnesium
What happenedThis use carried Grade C on observational evidence. PREDIMED (Guasch-Ferre et al., Journal of Nutrition, 2014; PMID 24259558) reports an association between the highest tertile of dietary magnesium intake and lower all-cause mortality, and Qu et al. (PLoS One, 2013; PMID 23520480) is a meta-analysis of prospective cohort studies. Nobody in either was randomized to magnesium, and both measure dietary intake rather than supplementation. EBL excludes observational data from grades under the same rule applied to the Finnish sauna cohorts and to the resistance-training mortality association, so this use is corrected to Grade D Route 1, no qualifying trial. The headline grade for magnesium is unchanged at C, which rests on the sleep use.
CorrectionTaurine, acute exercise performance: corrected from D to C
Recordtaurine
What happenedThis record characterized Balshaw et al. (Amino Acids, 2013; PMID 22855206) as Route 2, tested and no benefit. The trial reported the opposite: taurine significantly improved 3-km running time by 1.7%, p=0.013, in a double-blind randomized crossover design in eight trained middle-distance runners. The use is corrected to Grade C, which is what a single unrepeated trial in eight people supports, and the Route 2 designation is removed. The error was first surfaced by this repository's own FINDINGS_2026-08-x30d1.md, which flagged it and correctly declined to change the letter without adjudication.
CorrectionTime-restricted eating grade basis discloses a randomized cognition pilot and a countervailing mortality cohort
Recordsite-wide
What happenedA positive randomized pilot on cognition in mild cognitive impairment (PMID 41310471, n=46, untreated control) and an NHANES cohort of 31,044 adults reporting higher all-cause mortality for a last meal before 19:00 (PMID 42538400) are now both stated in the grade basis. Neither moves the letter: the pilot is too small and tests a different endpoint, the cohort is observational. Grade B unchanged.
What happenedThe dose field named a single daily dose and described the studied range as 250 to 500 mg. No cited trial used 500 mg, and the range was wrong in both directions. The baker's yeast beta-1,3/1,6-glucan trials used 250 mg per day; the insoluble brewers' yeast preparation trials used 900 mg per day. The field now states that there is no single studied dose, names each preparation with its own dose and duration, and records that the two preparations are not interchangeable.
What happenedEvery study named on the senolytics page was re-resolved against PubMed. The resveratrol trial in Alzheimer's disease reported no cognitive benefit and greater brain-volume loss rather than benefit (Turner, Neurology 2015), and the resveratrol blood-pressure trial reported LDL rising by 17.1 mg/dL on monotherapy (Riche, 2014). Five further citations named the wrong year, journal, or paper. Every claim on the page now carries a PubMed link.
CorrectionCommission disclosure corrected on 97 supplement pages
Recordsite-wide
What happened97 supplement pages carried a sentence saying that EBL might be paid when a reader bought through the link below it. That was not true. EBL is paid nothing on any item carrying an evidence grade, and its only product income is device hardware, which carries no grade. The sentence had been accurate when the site was built and nobody revisited the pages when the economics changed. A build gate now fails on any wording that asserts or implies payment on a graded item.
Corrected July 2026
Why this happens
A PubMed identifier is a run of digits and carries no meaning. You cannot look at 30536195 and 30306467 and tell which is the paper being described. Neither can a reviewer, and neither can a reader, because checking costs a click and nobody clicks. The failure has a signature: a real identifier, a real journal, the right author named in the prose, and a paper about something else entirely. That is not a typo. A typo gives you a dead link.
Two of the corrections above are worse than wrong papers. They are attributions to papers that, as far as EBL can establish, do not exist.
What changed
EBL no longer checks citations by hand, because hand-checking is what produced this list. The build now refuses to publish the site if any graded item cites nothing, if any PubMed ID appears on a page without being recorded in the database, if any page argues for a grade it does not have, or if any claim the site makes about itself is not true of its own data. Those checks run on every deploy and they do not get tired.
Educational use only. Not medical advice. EBL grades published human evidence and does not recommend treatment. · Privacy · Disclosure · Terms · Accessibility
Evidence Based Longevity, Inc. is owner-operated and edited by Arnold Sandlow, D.C., a California-licensed chiropractor. Evidence Based Longevity publishes in English only · Machine translations are not produced or reviewed by EBL for accuracy